Clinical trial results:
A Phase 3, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Rheumatoid Arthritis

Summary

EudraCT number	2012-003686-17
Trial protocol	IT SK CZ BE PL SE GB HU AT DK DE PT NL ES LV LT GR SI HR FR
Global end of trial date	12 November 2020

Results information

Result version number	v1
This version publication date	27 November 2021
First version publication date	27 November 2021

Trial information

Trial identification

Sponsor protocol code	I4V-MC-JADY

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01885078
WHO universal trial number (UTN)	-
Other trial identifiers	Trial Number: 14060

Notes:

Sponsors

Sponsor organisation name	Eli Lilly and Company
Sponsor organisation address	Lilly Corporate Center, Indianapolis, United States, 46285
Public contact	Available Mon Fri 9 AM 5 PM EST, Eli Lilly and Company, 877 CTLilly,
Scientific contact	Available Mon Fri 9 AM 5 PM EST, Eli Lilly and Company, 877 285-4559,

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	12 November 2020
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	12 November 2020
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective of the study is to evaluate the long-term safety and tolerability of baricitinib.

Protection of trial subjects:

This study was conducted in accordance with International Conference on Harmonization (ICH) Good Clinical Practice, and the principles of the Declaration of Helsinki, in addition to following the laws and regulations of the country or countries in which a study is conducted.

Background therapy:

Participants may continue to receive the background non-investigational, open-label conventional disease-modifying antirheumatic drugs (cDMARD), nonsteroidal anti-inflammatory drug (NSAID), corticosteroid, and other analgesic therapies they were receiving at completion of the originating study.

Evidence for comparator: -

Actual start date of recruitment	27 June 2013
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Korea, Republic of: 72
Country: Number of subjects enrolled	Netherlands: 1
Country: Number of subjects enrolled	Poland: 156
Country: Number of subjects enrolled	Portugal: 11
Country: Number of subjects enrolled	Slovakia: 27
Country: Number of subjects enrolled	Slovenia: 5
Country: Number of subjects enrolled	Spain: 86
Country: Number of subjects enrolled	Sweden: 3
Country: Number of subjects enrolled	United Kingdom: 26
Country: Number of subjects enrolled	Croatia: 9
Country: Number of subjects enrolled	Austria: 17
Country: Number of subjects enrolled	Belgium: 41
Country: Number of subjects enrolled	Czechia: 56
Country: Number of subjects enrolled	Denmark: 5
Country: Number of subjects enrolled	France: 36
Country: Number of subjects enrolled	Germany: 36
Country: Number of subjects enrolled	Greece: 8
Country: Number of subjects enrolled	Hungary: 60

Country: Number of subjects enrolled	Italy: 27
Country: Number of subjects enrolled	Latvia: 8
Country: Number of subjects enrolled	Lithuania: 21
Country: Number of subjects enrolled	United States: 488
Country: Number of subjects enrolled	Canada: 47
Country: Number of subjects enrolled	Argentina: 430
Country: Number of subjects enrolled	Australia: 32
Country: Number of subjects enrolled	Brazil: 30
Country: Number of subjects enrolled	India: 71
Country: Number of subjects enrolled	Israel: 27
Country: Number of subjects enrolled	China: 208
Country: Number of subjects enrolled	Japan: 328
Country: Number of subjects enrolled	Mexico: 214
Country: Number of subjects enrolled	Romania: 21
Country: Number of subjects enrolled	Russian Federation: 122
Country: Number of subjects enrolled	South Africa: 56
Country: Number of subjects enrolled	Taiwan: 81
Country: Number of subjects enrolled	Switzerland: 7
Country: Number of subjects enrolled	Turkey: 3
Worldwide total number of subjects	2876
EEA total number of subjects	634

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	2358
From 65 to 84 years	517
85 years and over	1

Subject disposition

Recruitment

Recruitment details:

The modified intent to treat (mITT) analysis set includes all enrolled participants who received at least one dose of study drug.

Pre-assignment

Screening details:

Participants who completed an originating study: I4V-MC-JADZ (NCT01711359), I4V-MC-JADV (NCT017103580, I4V-MC-JADX (NCT01721057), I4V-MC-JADW (NCT01721044), I4V-MC-JADA (NCT01185353), or I4V-MC-JAGS (NCT02265705) were eligible for enrollment into study JADY.

Period 1

Period 1 title	Treatment Period
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	JADZ 4 mg Baricitinib

Arm description:

4 mg Baricitinib administered orally once daily.

Arm type	Experimental
Investigational medicinal product name	Baricitinib
Investigational medicinal product code	LY3009104
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

4 mg Baricitinib administered orally once daily.

Arm title	JADV 4 mg Baricitinib

Arm description:

4 mg Baricitinib administered orally once daily.

Arm type	Experimental
Investigational medicinal product name	Baricitinib
Investigational medicinal product code	LY3009104
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

4 mg Baricitinib administered orally once daily.

Arm title	JADX 2 mg Baricitinib

Arm description:

2 mg Baricitinib administered orally once daily

Arm type	Experimental

Investigational medicinal product name	Baricitinib
Investigational medicinal product code	LY3009104
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

2 mg Baricitinib administered orally once daily.

Arm title	JADX 4 mg Baricitinib

Arm description:

4 mg Baricitinib administered orally once daily.

Arm type	Experimental
Investigational medicinal product name	Baricitinib
Investigational medicinal product code	LY3009104
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

4 mg Baricitinib administered orally once daily.

Arm title	JADW 2 mg Baricitinib

Arm description:

2 mg Baricitinib administered orally once daily.

Arm type	Experimental
Investigational medicinal product name	Baricitinib
Investigational medicinal product code	LY3009104
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

2 mg Baricitinib administered orally once daily.

Arm title	JADW 4 mg Baricitinib

Arm description:

4 mg Baricitinib administered orally once daily.

Arm type	Experimental
Investigational medicinal product name	Baricitinib
Investigational medicinal product code	LY3009104
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

4 mg Baricitinib administered orally once daily.

Investigational medicinal product name	Baricitinib
Investigational medicinal product code	LY3009104
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

4 mg Baricitinib administered orally once daily.

Arm title	JAGS 4 mg Baricitinib

Arm description:

4 mg Baricitinib administered orally once daily.

Arm type	Experimental
Investigational medicinal product name	Baricitinib
Investigational medicinal product code	LY3009104
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

4 mg Baricitinib administered orally once daily.

Arm title	JADA 4 mg Baricitinib

Arm description:

4 mg Baricitinib administered orally once daily.

Arm type	Experimental
Investigational medicinal product name	Baricitinib
Investigational medicinal product code	LY3009104
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

4 mg Baricitinib administered orally once daily.

Number of subjects in period 1	JADZ 4 mg Baricitinib	JADV 4 mg Baricitinib	JADX 2 mg Baricitinib
Started	451	1090	180
Received at Least One Dose of Study Drug	451	1090	180
Completed	19	64	49
Not completed	432	1026	131
Physician decision	19	21	5
Consent withdrawn by subject	72	131	25
Adverse event, non-fatal	52	136	30
Death	13	33	5
Unknown	-	-	-
Lost to follow-up	16	19	7
Sponsor decision	245	648	49
Lack of efficacy	12	33	10
Protocol deviation	3	5	-

Number of subjects in period 1	JADX 4 mg Baricitinib	JADW 2 mg Baricitinib	JADW 4 mg Baricitinib
Started	403	117	331
Received at Least One Dose of Study Drug	403	117	331
Completed	120	27	81
Not completed	283	90	250
Physician decision	12	9	24
Consent withdrawn by subject	63	15	34

Adverse event, non-fatal	73	17	72
Death	9	2	10
Unknown	1	-	-
Lost to follow-up	9	2	8
Sponsor decision	90	20	38
Lack of efficacy	23	24	58
Protocol deviation	3	1	6

Number of subjects in period 1	JAGS 4 mg Baricitinib	JADA 4 mg Baricitinib
Started	221	83
Received at Least One Dose of Study Drug	221	83
Completed	0	55
Not completed	221	28
Physician decision	4	3
Consent withdrawn by subject	17	10
Adverse event, non-fatal	24	5
Death	3	2
Unknown	-	-
Lost to follow-up	2	-
Sponsor decision	162	3
Lack of efficacy	9	5
Protocol deviation	-	-

Period 2	
Period 2 title	Step-down
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer, Assessor

Arms	
Are arms mutually exclusive?	No
Arm title	2 mg Baricitinib Step-down

Arm description: -

Arm type	Experimental
Investigational medicinal product name	Baricitinib
Investigational medicinal product code	LY3009104
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

2 mg Baricitinib administered orally once daily in the Step-down period.

Arm title	4 mg Baricitinib Step-down
Arm description: -	
Arm type	Experimental
Investigational medicinal product name	Baricitinib
Investigational medicinal product code	LY3009104
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

4 mg Baricitinib administered orally once daily in the Step-down period.

Number of subjects in period 2	2 mg Baricitinib Step-down	4 mg Baricitinib Step-down
Started	592	594
Completed	523	533
Not completed	69	61
Consent withdrawn by subject	25	15
Physician decision	7	2
Adverse event, non-fatal	29	38
Death	4	3
Sponsor decision	1	1
Lost to follow-up	1	1
Lack of efficacy	1	-
Protocol deviation	1	1

Baseline characteristics

Reporting groups	
Reporting group title	Treatment Period
Reporting group description:	
All participants who received at least one dose of study drug.	

Reporting group values	Treatment Period	Total	
Number of subjects	2876	2876	
Age categorical Units: Subjects			
Adults (18-64 years)	2358	2358	
From 65-84 years	517	517	
85 years and over	1	1	
Gender categorical Units: Subjects			
Female	2262	2262	
Male	614	614	
Race Units: Subjects			
American Indian or Alaska Native	143	143	
Asian	781	781	
Native Hawaiian or Other Pacific Islander	1	1	
Black or African American	64	64	
White	1859	1859	
More than one race	23	23	
Unknown or Not Reported	5	5	
Region of Enrollment Units: Subjects			
United States	488	488	
Czechia	56	56	
Portugal	11	11	
Russia	122	122	
Greece	8	8	
South Korea	72	72	
Latvia	8	8	
Sweden	3	3	
Austria	17	17	
Netherlands	1	1	
China	208	208	
Poland	156	156	
Brazil	30	30	
Slovenia	5	5	
Slovakia	27	27	
France	36	36	
Lithuania	21	21	
Croatia	9	9	
Argentina	430	430	

Romania	21	21	
Hungary	60	60	
Japan	328	328	
United Kingdom	26	26	
Switzerland	7	7	
India	71	71	
Spain	86	86	
Canada	47	47	
Turkey	3	3	
Belgium	41	41	
Taiwan	81	81	
Denmark	5	5	
South Africa	56	56	
Italy	27	27	
Mexico	214	214	
Israel	27	27	
Australia	32	32	
Germany	36	36	

Subject analysis sets

Subject analysis set title	2 mg Baricitinib
Subject analysis set type	Modified intention-to-treat
Subject analysis set description: 2 mg Baricitinib administered orally once daily.	
Subject analysis set title	4 mg Baricitinib
Subject analysis set type	Modified intention-to-treat
Subject analysis set description: 4 mg Baricitinib administered orally once daily.	

Reporting group values	2 mg Baricitinib	4 mg Baricitinib	
Number of subjects	297	2579	
Age categorical Units: Subjects			
Adults (18-64 years)	236	2122	
From 65-84 years	61	456	
85 years and over	0	1	
Gender categorical Units: Subjects			
Female	231	2031	
Male	66	548	
Race Units: Subjects			
American Indian or Alaska Native	7	136	
Asian	56	725	
Native Hawaiian or Other Pacific Islander	0	1	
Black or African American	16	48	
White	217	1642	
More than one race	1	22	
Unknown or Not Reported	0	5	

Region of Enrollment Units: Subjects			
United States	91	397	
Czechia	3	53	
Portugal	2	9	
Russia	10	112	
Greece	2	6	
South Korea	9	63	
Latvia	0	8	
Sweden	0	3	
Austria	3	14	
Netherlands	1	0	
China	0	208	
Poland	20	136	
Brazil	0	30	
Slovenia	0	5	
Slovakia	3	24	
France	6	30	
Lithuania	0	21	
Croatia	2	7	
Argentina	12	412	
Romania	2	19	
Hungary	8	52	
Japan	7	321	
United Kingdom	4	22	
Switzerland	0	7	
India	16	55	
Spain	15	71	
Canada	11	36	
Turkey	1	2	
Belgium	3	38	
Taiwan	23	58	
Denmark	2	3	
South Africa	0	56	
Italy	6	21	
Mexico	13	201	
Israel	6	21	
Australia	6	26	
Germany	4	32	

End points

End points reporting groups

Reporting group title	JADZ 4 mg Baricitinib
Reporting group description: 4 mg Baricitinib administered orally once daily.	
Reporting group title	JADV 4 mg Baricitinib
Reporting group description: 4 mg Baricitinib administered orally once daily.	
Reporting group title	JADX 2 mg Baricitinib
Reporting group description: 2 mg Baricitinib administered orally once daily	
Reporting group title	JADX 4 mg Baricitinib
Reporting group description: 4 mg Baricitinib administered orally once daily.	
Reporting group title	JADW 2 mg Baricitinib
Reporting group description: 2 mg Baricitinib administered orally once daily.	
Reporting group title	JADW 4 mg Baricitinib
Reporting group description: 4 mg Baricitinib administered orally once daily.	
Reporting group title	JAGS 4 mg Baricitinib
Reporting group description: 4 mg Baricitinib administered orally once daily.	
Reporting group title	JADA 4 mg Baricitinib
Reporting group description: 4 mg Baricitinib administered orally once daily.	
Reporting group title	2 mg Baricitinib Step-down
Reporting group description: -	
Reporting group title	4 mg Baricitinib Step-down
Reporting group description: -	
Subject analysis set title	2 mg Baricitinib
Subject analysis set type	Modified intention-to-treat
Subject analysis set description: 2 mg Baricitinib administered orally once daily.	
Subject analysis set title	4 mg Baricitinib
Subject analysis set type	Modified intention-to-treat
Subject analysis set description: 4 mg Baricitinib administered orally once daily.	

Primary: Number of Participants Who Experienced Adverse Events (AEs) or Serious AE

End point title	Number of Participants Who Experienced Adverse Events (AEs) or Serious AE[1]

End point description:

An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can be any unfavorable and unintended sign (i.e., abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. Non-serious AEs are reported at a threshold of 5%.

An SAE is an AE from this study that results in any of the following: death, initial or prolonged inpatient

hospitalization, a life-threatening experience, persistent or significant disability/incapacity, congenital anomaly/birth defect, considered significant by the investigator for any other reason

A summary of serious adverse events (SAEs) and other non-serious adverse events (AEs), regardless of causality, were reported in the Reported Adverse Events module.

End point type	Primary

End point timeframe:

Baseline through 84 Months

Analysis Population Description (APD): All enrolled participants who received at least 1 dose of study drug and did not discontinue the study for the reason 'Lost to Follow-up' at the first postbaseline visit in study JADY.

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical comparison was not conducted on safety outcome measure.

End point values	2 mg Baricitinib Step-down	4 mg Baricitinib Step-down	2 mg Baricitinib	4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	592	594	297	2579
Units: Count of participants				
Adverse Events	270	315	234	153
Serious Adverse Events	164	178	127	518

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR20

End point title	Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR20

End point description:

ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants analyzed) * 100

APD: All enrolled participants who received at least one dose of study drug and completed at least 48 weeks in study JADY.

End point type	Secondary

End point timeframe:

Year 1, 3 and 5 after entry into JADY

End point values	JADZ 4 mg Baricitinib	JADV 4 mg Baricitinib	JADX 2 mg Baricitinib	JADX 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	419	1034	169	366
Units: Percentage of Participants				
number (confidence interval 95%)				
Year 1	92.6 (89.7 to 94.7)	88.4 (86.3 to 90.2)	79.3 (72.6 to 84.7)	79.5 (75.1 to 83.3)
Year 3	78.3 (74.1 to 82.0)	76.6 (73.9 to 79.1)	71.6 (64.4 to 77.9)	70.5 (65.6 to 74.9)
Year 5	67.3 (62.7 to 71.6)	65.6 (62.6 to 68.4)	60.4 (52.8 to 67.4)	56.0 (50.9 to 61.0)

End point values	JADW 2 mg Baricitinib	JADW 4 mg Baricitinib	JAGS 4 mg Baricitinib	JADA 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	101	274	210	78
Units: Percentage of Participants				
number (confidence interval 95%)				
Year 1	72.3 (62.9 to 80.1)	70.8 (65.2 to 75.9)	86.7 (81.4 to 90.6)	75.6 (65.1 to 83.8)
Year 3	57.4 (47.7 to 66.6)	55.8 (49.9 to 61.6)	73.8 (67.5 to 79.3)	71.8 (61.0 to 80.6)
Year 5	50.5 (40.9 to 60.0)	43.1 (37.3 to 49.0)	24.8 (19.4 to 31.0)	60.3 (49.2 to 70.4)

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR50

End point title	Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR50

End point description:

ACR 50 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR50 Responder is a participant who had ≥50% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥50% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Percentage of participants achieving ACR20 response = (number of ACR50 responders) / (number of participants analyzed) * 100

End point type	Secondary

End point timeframe:

Year 1, 3 and 5 after entry into JADY

End point values	JADZ 4 mg Baricitinib	JADV 4 mg Baricitinib	JADX 2 mg Baricitinib	JADX 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	419	1034	169	366
Units: Percentage of participants				
number (confidence interval 95%)				
Year 1	80.0 (75.9 to 83.5)	67.7 (64.8 to 70.5)	58.0 (50.5 to 65.2)	58.2 (53.1 to 63.1)
Year 3	67.8 (63.2 to 72.1)	61.6 (58.6 to 64.5)	49.7 (42.3 to 57.2)	53.3 (48.2 to 58.3)
Year 5	59.9 (55.1 to 64.5)	52.7 (49.7 to 55.7)	44.4 (37.1 to 51.9)	43.2 (38.2 to 48.3)

End point values	JADW 2 mg Baricitinib	JADW 4 mg Baricitinib	JAGS 4 mg Baricitinib	JADA 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	101	274	210	78
Units: Percentage of participants				
number (confidence interval 95%)				
Year 1	45.5 (36.2 to 55.2)	43.8 (38.0 to 49.7)	69.0 (62.5 to 74.9)	43.6 (33.1 to 54.6)
Year 3	43.6 (34.3 to 53.3)	36.5 (31.0 to 42.3)	59.0 (52.3 to 65.5)	43.6 (33.1 to 54.6)
Year 5	37.6 (28.8 to 47.4)	32.1 (26.9 to 37.9)	18.6 (13.9 to 24.4)	37.2 (27.3 to 48.3)

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR70

End point title	Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR70

End point description:

ACR70 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR70 Responder is a participant who had ≥70% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥70% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Percentage of participants achieving ACR70 response = (number of ACR70 responders) / (number of participants analyzed) * 100

End point type	Secondary

End point timeframe:

Year 1, 3 and 5 after entry into JADY

End point values	JADZ 4 mg Baricitinib	JADV 4 mg Baricitinib	JADX 2 mg Baricitinib	JADX 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	419	1034	169	366
Units: Percentage of participants				
number (confidence interval 95%)				
Year 1	61.3 (56.6 to 65.9)	45.7 (42.7 to 48.8)	34.9 (28.1 to 42.4)	35.8 (31.1 to 40.8)
Year 3	54.4 (49.6 to 59.1)	44.1 (41.1 to 47.7)	35.5 (27.9 to 37.5)	32.5 (27.9 to 37.5)
Year 5	48.2 (43.5 to 53.0)	39.1 (36.1 to 42.1)	28.4 (22.1 to 35.6)	28.4 (24.0 to 33.2)

End point values	JADW 2 mg Baricitinib	JADW 4 mg Baricitinib	JAGS 4 mg Baricitinib	JADA 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	101	274	210	78
Units: Percentage of participants				
number (confidence interval 95%)				
Year 1	28.7 (20.8 to 38.2)	25.9 (21.1 to 31.4)	42.9 (36.4 to 49.6)	26.9 (18.3 to 37.7)
Year 3	24.8 (17.4 to 34.0)	21.5 (17.1 to 26.8)	35.2 (29.1 to 41.9)	21.8 (14.1 to 32.2)
Year 5	23.8 (16.5 to 32.9)	18.2 (14.1 to 23.2)	12.9 (9.0 to 18.1)	19.2 (12.0 to 29.3)

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Maintaining a Disease Activity Score (DAS28) High-Sensitivity C-Reactive Protein (hsCRP) ≤3.2

End point title	Percentage of Participants Maintaining a Disease Activity Score (DAS28) High-Sensitivity C-Reactive Protein (hsCRP) ≤3.2

End point description:

Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count-28 (TJC28), swollen joint count-28 (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). DAS28-CRP=0.56*square root (sqrt)(TJC28)+0.28*sqrt(SJC28)+0.36*natural log(CRP+1)+0.014*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity, and remission was DAS28-CRP <2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.

APD: All enrolled participants who received at least one dose of study drug and completed at least 48 weeks in study JADY.

End point type	Secondary

End point timeframe:

Year 1, 3 and 5 after entry into JADY

End point values	JADZ 4 mg Baricitinib	JADV 4 mg Baricitinib	JADX 2 mg Baricitinib	JADX 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	419	1034	169	366
Units: Percentage of participants				
number (confidence interval 95%)				
Year 1	81.9 (77.9 to 85.3)	71.9 (69.0 to 74.5)	66.3 (58.9 to 73.0)	68.6 (63.7 to 73.1)
Year 3	71.8 (67.3 to 75.9)	65.5 (62.5 to 68.3)	59.2 (51.6 to 66.3)	59.3 (54.2 to 64.2)
Year 5	61.1 (56.3 to 65.6)	58.9 (55.9 to 61.9)	46.7 (39.4 to 54.3)	50.0 (44.9 to 55.1)

End point values	JADW 2 mg Baricitinib	JADW 4 mg Baricitinib	JAGS 4 mg Baricitinib	JADA 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	101	274	210	78
Units: Percentage of participants				
number (confidence interval 95%)				
Year 1	50.5 (40.9 to 60.0)	51.1 (45.2 to 57.0)	72.4 (66.0 to 78.0)	59.0 (47.9 to 69.2)
Year 3	47.5 (38.1 to 57.2)	41.6 (35.9 to 47.5)	61.0 (54.2 to 67.3)	60.3 (49.2 to 70.4)
Year 5	44.6 (35.2 to 54.3)	34.3 (28.9 to 40.1)	21.0 (16.0 to 27.0)	53.8 (42.9 to 64.5)

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Maintaining a Disease Activity Score (DAS28) High-Sensitivity C-Reactive Protein (hsCRP) <2.6

End point title	Percentage of Participants Maintaining a Disease Activity Score (DAS28) High-Sensitivity C-Reactive Protein (hsCRP) <2.6

End point description:

DAS28 consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), ESR (millimeters per hour), and Patient's Global Assessment of Disease Activity. DAS28 was calculated using following formula: DAS28-ESR=0.56*square root (sqrt)(TJC28)+0.28*sqrt(SJC28)+0.70*natural log(ESR)+0.014*Patient's Global VAS. Total scores ranged from 1.0-9.4, where lower scores indicated less disease activity.

APD: All enrolled participants who received at least one dose of study drug and completed at least 48 weeks in study JADY.

End point type	Secondary

End point timeframe:

Year 1, 3 and 5 after entry into JADY

End point values	JADZ 4 mg Baricitinib	JADV 4 mg Baricitinib	JADX 2 mg Baricitinib	JADX 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	419	1034	169	366
Units: Percentage of participants				
number (confidence interval 95%)				
Year 1	65.6 (61.0 to 70.0)	52.3 (49.3 to 55.4)	50.9 (43.4 to 58.3)	46.2 (41.1 to 51.3)
Year 3	59.9 (55.1 to 64.5)	51.0 (47.9 to 54.0)	43.8 (36.5 to 51.3)	43.2 (38.2 to 48.3)
Year 5	51.1 (46.3 to 55.8)	44.0 (41.0 to 47.0)	36.1 (29.2 to 43.6)	37.7 (32.9 to 42.8)

End point values	JADW 2 mg Baricitinib	JADW 4 mg Baricitinib	JAGS 4 mg Baricitinib	JADA 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	101	274	210	78
Units: Percentage of participants				
number (confidence interval 95%)				
Year 1	34.7 (26.1 to 44.3)	32.8 (27.6 to 38.6)	52.4 (45.6 to 59.0)	44.9 (34.3 to 55.9)
Year 3	31.7 (23.4 to 41.3)	26.3 (21.4 to 31.8)	38.6 (32.2 to 45.3)	35.9 (26.1 to 47.0)
Year 5	29.7 (21.7 to 39.2)	26.6 (21.8 to 32.2)	13.3 (9.4 to 18.6)	43.6 (33.1 to 54.6)

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Maintaining American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean Remission Response

End point title	Percentage of Participants Maintaining American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean Remission Response

End point description:

Boolean-based definition of remission, all 4 criteria below must be met: tender joint count (TJC28) <=1, swollen joint count (SJC28) <=1, hsCRP <=1 milligram per deciliter (mg/dL), Patient Global Assessment of Disease Activity using visual analog scale (VAS) <=1 cm.

End point type	Secondary

End point timeframe:

Year 1, 3, and 5 after entry into JADY

End point values	JADZ 4 mg Baricitinib	JADV 4 mg Baricitinib	JADX 2 mg Baricitinib	JADX 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	419	1034	169	366
Units: Percentage of participants				
number (confidence interval 95%)				
Year 1	30.5 (26.3 to 35.1)	20.8 (18.4 to 23.4)	17.8 (12.7 to 24.2)	17.8 (14.2 to 22.0)
Year 3	30.8 (26.6 to 35.4)	20.3 (18.0 to 22.9)	16.6 (11.7 to 22.9)	15.0 (11.7 to 19.1)
Year 5	26.5 (22.5 to 30.9)	17.7 (15.5 to 20.1)	13.6 (9.2 to 19.6)	14.2 (11.0 to 18.2)

End point values	JADW 2 mg Baricitinib	JADW 4 mg Baricitinib	JAGS 4 mg Baricitinib	JADA 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	101	274	210	78
Units: Percentage of participants				
number (confidence interval 95%)				
Year 1	8.9 (4.8 to 16.1)	9.5 (6.6 to 13.5)	17.1 (12.6 to 22.8)	12.8 (7.1 to 22.0)
Year 3	9.9 (5.5 to 17.3)	8.0 (5.4 to 11.9)	11.9 (8.2 to 17.0)	15.4 (9.0 to 25.0)
Year 5	6.9 (3.4 to 13.6)	7.3 (4.8 to 11.0)	5.2 (2.9 to 9.1)	15.4 (9.0 to 25.0)

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline of Originating Study in Modified Total Sharp Score (mTSS)

End point title	Change From Baseline of Originating Study in Modified Total Sharp Score (mTSS)

End point description:

X-rays of the hands/wrists and feet were scored for structural progression as measured using the mTSS. This methodology quantified the extent of bone erosions and joint space narrowing (JSN) for 44 and 42 joints, with higher scores representing greater damage. The mTSS at a time point is the sum of the erosion (range from 0 to 280) and JSN (range from 0 to 168) scores, for a maximum score of 448. Least Squares Mean (LSM) was calculated using a mixed model for repeated measures (MMRM) with treatment, visit, treatment-by-visit-interactions as fixed categorical effects and baseline and baseline-by-visit-interactions as fixed continuous effects.

APD: All enrolled participants who received at least 1 dose of study drug in JADY with available baseline (from originating study) and at least 1 postbaseline x-ray assessment (collected in JADY) and Year 1 data. Year 1 data not available, 0 participants analyzed. JADW and JADA, 0 participants analyzed due to no data collected in this study

End point type	Secondary

End point timeframe:

Baseline, Year 1, Baseline, Year 3; Baseline, Year 5
N represents treatments arms consecutively which corresponds with listings in the header.

End point values	JADZ 4 mg Baricitinib	JADV 4 mg Baricitinib	JADX 2 mg Baricitinib	JADX 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	387[2]	870[3]	137[4]	301[5]
Units: Score on a scale				
least squares mean (confidence interval 95%)				
Year 1: N=0, N=0, N=0, N=0, N=0, N=0, N=0, N=0	9999 (9999 to 9999)	9999 (9999 to 9999)	9999 (9999 to 9999)	9999 (9999 to 9999)
Year 3:N=387,N=943,N=137,N=301,N=0,N=	1.03 (0.94 to 1.67)	1.64 (1.38 to 1.90)	1.13 (0.61 to 1.66)	1.13 (0.78 to 1.48)
Year 5:N=349,N=870,N=127,N=276,N=0,N=	1.64 (1.18 to 2.09)	2.18 (1.85 to 2.51)	1.32 (0.69 to 1.96)	1.58 (1.15 to 2.02)

Notes:

[2] - 9999=Data not available, zero participants analyzed.

[3] - 9999=Data not available, zero participants analyzed.

[4] - 9999=Data not available, zero participants analyzed.

[5] - 9999=Data not available, zero participants analyzed.

End point values	JADW 2 mg Baricitinib	JADW 4 mg Baricitinib	JAGS 4 mg Baricitinib	JADA 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0[6]	0[7]	203[8]	0[9]
Units: Score on a scale				
least squares mean (confidence interval 95%)				
Year 1: N=0, N=0, N=0, N=0, N=0, N=0, N=0, N=0	(to)	(to)	9999 (9999 to 9999)	(to)
Year 3:N=387,N=943,N=137,N=301,N=0,N=	(to)	(to)	1.20 (0.61 to 1.80)	(to)
Year 5:N=349,N=870,N=127,N=276,N=0,N=	(to)	(to)	9999 (9999 to 9999)	(to)

Notes:

[6] - Zero participants analyzed due to no data collected in this study or originating study.

[7] - Zero participants analyzed due to no data collected in this study or originating study.

[8] - 9999 = Data not available, zero participants analyzed.

[9] - Zero participants analyzed due to no data collected in this study or originating study.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With mTSS Change ≤0

End point title	Percentage of Participants With mTSS Change ≤0

End point description:

X-rays of the hands/wrists and feet were scored for structural progression as measured using the mTSS. This methodology quantified the extent of bone erosions and joint space narrowing (JSN) for 44 and 42 joints, with higher scores representing greater damage. The mTSS at a time point is the sum of the erosion (range from 0 to 280) and JSN (range from 0 to 168) scores, for a maximum score of 448, with higher scores representing greater damage.

APD: All enrolled participants who received at least one dose of study drug. Year 1 data not available, zero participants analyzed. JADW and JADA, zero participants analyzed due to no data collected in this study or originating study.

End point type	Secondary

End point timeframe:

Year 1, 3, and 5 after entry into JADY

End point values	JADZ 4 mg Baricitinib	JADV 4 mg Baricitinib	JADX 2 mg Baricitinib	JADX 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	419[10]	1034[11]	169[12]	366[13]
Units: Percentage of participants				
number (confidence interval 95%)				
Year 1	9999 (9999 to 9999)	9999 (9999 to 9999)	9999 (9999 to 9999)	9999 (9999 to 9999)
Year 3	53.5 (48.7 to 58.2)	53.0 (50.0 to 56.0)	0.6 (0.1 to 3.3)	0.8 (0.3 to 2.4)
Year 5	1.7 (0.8 to 3.4)	0.6 (0.3 to 1.3)	0.0 (0.0 to 2.2)	0.5 (0.1 to 2.0)

Notes:

[10] - 9999 = Data not available, zero participants analyzed.

[11] - 9999 = Data not available, zero participants analyzed.

[12] - 9999 = Data not available, zero participants analyzed.

[13] - 9999 = Data not available, zero participants analyzed.

End point values	JADW 2 mg Baricitinib	JADW 4 mg Baricitinib	JAGS 4 mg Baricitinib	JADA 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0[14]	0[15]	210[16]	0[17]
Units: Percentage of participants				
number (confidence interval 95%)				
Year 1	(to)	(to)	9999 (9999 to 9999)	(to)
Year 3	(to)	(to)	0.0 (0.0 to 1.8)	(to)
Year 5	(to)	(to)	0.0 (0.0 to 1.8)	(to)

Notes:

[14] - No data collected; zero participants analyzed..

[15] - No data collected; zero participants analyzed.

[16] - 9999 = Data not available, zero participants analyzed.

[17] - No data collected; zero participants analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline of Originating Study in Joint Space Narrowing

End point title	Change From Baseline of Originating Study in Joint Space Narrowing

End point description:

X-rays of the hands/wrists and feet were assessed for joint space narrowing (JSN) and bone erosions. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, is scored from 0 to 4, with 0 indicating no (normal) JSN and 4 indicating complete loss of joint space, bony ankylosis or luxation. JSN scores ranged from 0-168. A score of 0 would indicate no change and higher scores represent a worsening of joint space narrowing.

APD: All enrolled participants treated with at least 1 dose of study drug in JADY with available baseline

(from originating study) and at least 1 postbaseline x-ray assessment (collected in JADY). JADW and JADA, zero participants analyzed due to no data collected in this study or originating study.

End point type	Secondary

End point timeframe:

Baseline, Year 3; Baseline, Year 5
N represents treatments arms consecutively which corresponds with listings in the header.

End point values	JADZ 4 mg Baricitinib	JADV 4 mg Baricitinib	JADX 2 mg Baricitinib	JADX 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	387	943	137	301
Units: Score on a scale				
least squares mean (confidence interval 95%)				
Year 1: N=0, N=0, N=0, N=0, N=0, N=0, N=0, N=0, N=0	9999 (9999 to 9999)	9999 (9999 to 9999)	9999 (9999 to 9999)	9999 (9999 to 9999)
Year 3:N=387,N=943,N=137,N=301,N=0,N=	0.45 (0.26 to 0.63)	0.72 (0.59 to 0.86)	0.54 (0.25 to 0.83)	0.44 (0.24 to 0.63)
Year 5:N=349, N-870,N=127,N=276, N=0, N=0, N=0,N=0	0.59 (0.36 to 0.83)	1.00 (0.84 to 1.17)	0.68 (0.34 to 1.02)	0.60 (0.37 to 0.83)

End point values	JADW 2 mg Baricitinib	JADW 4 mg Baricitinib	JAGS 4 mg Baricitinib	JADA 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0[18]	0[19]	203[20]	0[21]
Units: Score on a scale				
least squares mean (confidence interval 95%)				
Year 1: N=0, N=0, N=0, N=0, N=0, N=0, N=0, N=0, N=0	(to)	(to)	9999 (9999 to 9999)	(to)
Year 3:N=387,N=943,N=137,N=301,N=0,N=	(to)	(to)	0.52 (0.23 to 0.82)	(to)
Year 5:N=349, N-870,N=127,N=276, N=0, N=0, N=0,N=0	(to)	(to)	9999 (9999 to 9999)	(to)

Notes:

[18] - No data collected; zero participants analyzed.

[19] - No data collected; zero participants analyzed.

[20] - 9999=Data not available, zero participants analyzed.

[21] - No data collected; zero participants analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline of Originating Study in Duration of Morning Stiffness

End point title	Change From Baseline of Originating Study in Duration of Morning Stiffness

End point description:

Participants reported the duration of their morning joint stiffness (MJS) in hours and minutes. The participants were asked about their duration of morning joint stiffness on the day prior to the study visit

to capture actual symptoms, since the participant may have had an atypical morning routine on the day of the study visit. If morning joint stiffness duration was longer than 12 hours (720 minutes), it was truncated to 720 minutes for statistical presentations and analyses. A decrease in duration of morning joint stiffness indicated an improvement in the participant's condition.

APD: All enrolled participants who received at least one dose of study drug in JADY and had evaluable morning stiffness data. There were no baseline data for JADX

End point type	Secondary

End point timeframe:

Baseline, Year1 ; Baseline, Year 3; Baseline, Year 5
N represents treatments arms consecutively which corresponds with listings in the header.

End point values	JADZ 4 mg Baricitinib	JADV 4 mg Baricitinib	JADX 2 mg Baricitinib	JADX 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	450	633	0[22]	0[23]
Units: Minutes				
arithmetic mean (standard deviation)				
Yr 1:N=450,N-633,N=0,N=0,N=110,N=308,N=221,N=	-102.72 (± 155.27)	-73.53 (± 144.22)	()	()
Yr 3:N=387,N=556,N=0,N=0,N=81,N=222	-112.41 (± 159.78)	-77.78 (± 141.01)	()	()
Yr 5:N=330,N=470,N=0,N=0,N=70,N-169,N=128,N=57	-111.45 (± 164.74)	-82.48 (± 137.23)	()	()

Notes:

[22] - No data collected; zero participants analyzed.

[23] - No data collected; zero participants analyzed.

End point values	JADW 2 mg Baricitinib	JADW 4 mg Baricitinib	JAGS 4 mg Baricitinib	JADA 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	110	308	221	78
Units: Minutes				
arithmetic mean (standard deviation)				
Yr 1:N=450,N-633,N=0,N=0,N=110,N=308,N=221,N=	-75.07 (± 139.00)	73.88 (± 149.55)	-68.74 (± 148.34)	-37.12 (± 61.34)
Yr 3:N=387,N=556,N=0,N=0,N=81,N=222	-84.60 (± 127.80)	-67.79 (± 154.05)	-90.61 (± 147.70)	-47.13 (± 52.97)
Yr 5:N=330,N=470,N=0,N=0,N=70,N-169,N=128,N=57	88.37 (± 146.73)	-91.57 (± 163.88)	-92.75 (± 125.39)	-45.89 (± 60.43)

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline of Originating Study in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Health State Scores (UK)

End point title	Change From Baseline of Originating Study in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Health State Scores (UK)

End point description:

The European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. The first component is a descriptive system of the respondent's health comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1, and the United States (US) algorithm, with scores ranging from -0.109 to 1. A higher score indicates better health state.

APD: All enrolled participants who received at least 1 dose of study drug and had evaluable EQ-5D-5L data. EQ-5D-5L data was not collected during the JADA originating study, zero participants analyzed.

End point type	Secondary

End point timeframe:

Baseline, Year 1; Baseline, Year 3; Baseline, Year 5

End point values	JADZ 4 mg Baricitinib	JADV 4 mg Baricitinib	JADX 2 mg Baricitinib	JADX 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	450	1088	171	383
Units: Score on a scale				
arithmetic mean (standard deviation)				
Yr1:N=450,N=1088,N=171,N=383,N=108,N=305,N=221,N=0	0.28 (± 0.26)	0.23 (± 0.24)	0.19 (± 0.26)	0.20 (± 0.23)
Yr3:N=386,N=952,N=146,N=309,N=80,N=219,N=190,N=0	0.33 (± 0.24)	0.24 (± 0.25)	0.20 (± 0.26)	0.21 (± 0.26)
Yr5:N=330,N=820,N=122,N=264,N=70,N=169,N=127,N=0	0.35 (± 0.24)	0.26 (± 0.26)	0.19 (± 0.25)	0.20 (± 0.26)

End point values	JADW 2 mg Baricitinib	JADW 4 mg Baricitinib	JAGS 4 mg Baricitinib	JADA 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	108	305	221	0[24]
Units: Score on a scale				
arithmetic mean (standard deviation)				
Yr1:N=450,N=1088,N=171,N=383,N=108,N=305,N=221,N=0	0.21 (± 0.22)	0.19 (± 0.24)	0.20 (± 0.26)	()
Yr3:N=386,N=952,N=146,N=309,N=80,N=219,N=190,N=0	0.21 (± 0.22)	0.22 (± 0.25)	0.24 (± 0.24)	()
Yr5:N=330,N=820,N=122,N=264,N=70,N=169,N=127,N=0	0.21 (± 0.22)	0.22 (± 0.30)	0.25 (± 0.26)	()

Notes:

[24] - Zero participants analyzed; data not collected.

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline of Originating Study in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Halth State Scores (US)

End point title	Change From Baseline of Originating Study in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Halth State Scores

	(US)

End point description:

The European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. The first component is a descriptive system of the respondent's health comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1, and the United States (US) algorithm, with scores ranging from -0.109 to 1. A higher score indicates better health state.

APD: All enrolled participants who received at least 1 dose of study drug and had evaluable EQ-5D-5L data. EQ-5D-5L data was not collected during the JADA originating study, zero participants analyzed.

End point type	Secondary

End point timeframe:

Baseline, Year 1; Baseline Year 3; Baseline, Year 5
N represents treatments arms consecutively which corresponds with listings in the header.

End point values	JADZ 4 mg Baricitinib	JADV 4 mg Baricitinib	JADX 2 mg Baricitinib	JADX 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	450	1088	171	383
Units: Score on a scale				
arithmetic mean (standard deviation)				
Yr1:N=450,N=1088,N=171,N=383,N=108,N=305,N=221,N=0	0.19 (± 0.18)	0.16 (± 0.17)	0.13 (± 0.18)	0.14 (± 0.16)
Yr3:N=386,N=952,N=146,N=309,N=80,N=219,N=190,N=0	0.23 (± 0.17)	0.17 (± 0.17)	0.15 (± 0.18)	0.15 (± 0.18)
Yr5:N=330,N=820,N=122,N=264,N=70,N=169,N=127,N=0	0.24 (± 0.16)	0.18 (± 0.18)	0.13 (± 0.17)	0.14 (± 0.18)

End point values	JADW 2 mg Baricitinib	JADW 4 mg Baricitinib	JAGS 4 mg Baricitinib	JADA 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	108	305	221	0[25]
Units: Score on a scale				
arithmetic mean (standard deviation)				
Yr1:N=450,N=1088,N=171,N=383,N=108,N=305,N=221,N=0	0.14 (± 0.15)	0.13 (± 0.16)	0.14 (± 0.18)	()
Yr3:N=386,N=952,N=146,N=309,N=80,N=219,N=190,N=0	0.14 (± 0.15)	0.15 (± 0.17)	0.17 (± 0.17)	()
Yr5:N=330,N=820,N=122,N=264,N=70,N=169,N=127,N=0	0.15 (± 0.15)	0.15 (± 0.20)	0.18 (± 0.18)	()

Notes:

[25] - Zero participants analyzed; data not collected.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Maintaining a Clinical Disease Activity Index Score (CDAI) ≤10

End point title	Percentage of Participants Maintaining a Clinical Disease Activity Index Score (CDAI) ≤10

End point description:

The CDAI is a tool for measurement of disease activity in RA that does not require a laboratory component and was scored by the investigative site. It integrates TJC28 (scored 0-28 with higher scores indicating higher disease activity), SJC28 (scored 0-28 with higher scores indicating higher disease activity), Patient's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity), and Physician's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity). The CDAI is calculated by summing the values of the 4 components. CDAI scores range from 0 to 76; lower scores indicated lower disease activity. A negative change from baseline indicates improvement in condition.

APD: All enrolled participants who received at least one dose of study drug and completed at least 48 weeks in study JADY.

End point type	Secondary

End point timeframe:

Year 3 and Year 5 after entry into JADY

End point values	JADZ 4 mg Baricitinib	JADV 4 mg Baricitinib	JADX 2 mg Baricitinib	JADX 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	419	1034	169	366
Units: Percentage of participants				
number (confidence interval 95%)				
Year 1	81.6 (77.6 to 85.0)	75.3 (72.6 to 77.9)	68.6 (61.3 to 75.2)	69.9 (65.1 to 74.4)
Year 3	73.3 (68.8 to 77.3)	67.7 (64.8 to 70.5)	60.4 (52.8 to 67.4)	60.4 (55.3 to 65.3)
Year 5	61.6 (56.8 to 66.1)	61.1 (58.1 to 64.0)	51.5 (44.0 to 58.9)	54.6 (49.5 to 59.7)

End point values	JADW 2 mg Baricitinib	JADW 4 mg Baricitinib	JAGS 4 mg Baricitinib	JADA 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	101	274	210	78
Units: Percentage of participants				
number (confidence interval 95%)				
Year 1	52.5 (42.8 to 61.9)	50.7 (44.8 to 56.6)	73.3 (67.0 to 78.9)	60.3 (49.2 to 70.4)
Year 3	49.5 (40.0 to 59.1)	44.5 (38.8 to 50.4)	61.4 (54.7 to 67.8)	56.4 (45.4 to 66.9)
Year 5	44.6 (35.2 to 54.3)	35.4 (30.0 to 41.2)	21.9 (16.8 to 28.0)	56.4 (45.4 to 66.9)

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Maintaining a Clinical Disease Activity Index

Score (CDAI) ≤2.8

End point title	Percentage of Participants Maintaining a Clinical Disease Activity Index Score (CDAI) ≤2.8

End point description:

The CDAI is a tool for measurement of disease activity in RA that does not require a laboratory component and was scored by the investigative site. It integrates TJC28 (scored 0-28 with higher scores indicating higher disease activity), SJC28 (scored 0-28 with higher scores indicating higher disease activity), Patient's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity), and Physician's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity). The CDAI is calculated by summing the values of the 4 components. CDAI scores range from 0 to 76; lower scores indicated lower disease activity. A negative change from baseline indicates improvement in condition.
APD: All enrolled participants who received at least one dose of study drug and completed at least 48 weeks in study JADY.

End point type	Secondary

End point timeframe:

Year 3 and Year 5 after entry into JADY

End point values	JADZ 4 mg Baricitinib	JADV 4 mg Baricitinib	JADX 2 mg Baricitinib	JADX 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	419	1034	169	366
Units: Percentage of participants				
number (confidence interval 95%)				
Year 1	44.9 (40.2 to 49.7)	28.3 (25.7 to 31.2)	21.9 (16.3 to 28.7)	25.1 (21.0 to 29.8)
Year 3	40.1 (35.5 to 44.9)	30.0 (27.3 to 32.8)	21.9 (16.3 to 28.7)	23.5 (19.4 to 28.1)
Year 5	33.9 (29.5 to 38.6)	25.0 (22.5 to 27.8)	19.5 (14.3 to 26.2)	22.4 (18.4 to 27.0)

End point values	JADW 2 mg Baricitinib	JADW 4 mg Baricitinib	JAGS 4 mg Baricitinib	JADA 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	101	274	210	78
Units: Percentage of participants				
number (confidence interval 95%)				
Year 1	16.8 (10.8 to 25.3)	13.5 (10.0 to 18.1)	22.9 (17.7 to 29.0)	14.1 (8.1 to 23.5)
Year 3	22.8 (15.7 to 31.9)	15.0 (11.2 to 19.7)	18.6 (13.9 to 24.4)	20.5 (13.0 to 30.8)
Year 5	15.8 (10.0 to 24.2)	12.8 (9.3 to 17.2)	8.1 (5.1 to 12.6)	19.2 (12.0 to 29.3)

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Maintaining a Health Assessment Questionnaire Disability Index (HAQ-DI) Improvement ≥0.22

End point title	Percentage of Participants Maintaining a Health Assessment Questionnaire Disability Index (HAQ-DI) Improvement ≥0.22

End point description:

The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty [0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition. An improvement of 0.22 or 0.3 points on the HAQ-DI has been identified as a minimal clinically important difference in Rheumatoid Arthritis participants.

APD: All enrolled participants who received at least one dose of study drug and completed at least 48 weeks in study JADY.

End point type	Secondary

End point timeframe:

Year 3 and Year 5 after entry into JADY

End point values	JADZ 4 mg Baricitinib	JADV 4 mg Baricitinib	JADX 2 mg Baricitinib	JADX 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	419	1034	169	366
Units: Percentage of participants				
number (confidence interval 95%)				
Year 1	89.7 (86.5 to 92.3)	81.4 (78.9 to 83.7)	78.7 (71.9 to 84.2)	75.4 (70.7 to 79.5)
Year 3	75.4 (71.1 to 79.3)	70.4 (67.6 to 73.1)	64.5 (57.0 to 71.3)	63.4 (58.3 to 68.2)
Year 5	65.2 (60.5 to 69.6)	58.5 (55.5 to 61.5)	51.5 (44.0 to 58.9)	51.4 (46.3 to 56.4)

End point values	JADW 2 mg Baricitinib	JADW 4 mg Baricitinib	JAGS 4 mg Baricitinib	JADA 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	101	274	210	78
Units: Percentage of participants				
number (confidence interval 95%)				
Year 1	74.3 (65.0 to 81.8)	69.3 (63.6 to 74.5)	80.0 (74.1 to 84.8)	48.7 (37.9 to 59.6)
Year 3	56.4 (46.7 to 65.7)	54.4 (48.5 to 60.2)	68.1 (61.5 to 74.0)	47.4 (36.7 to 58.4)
Year 5	50.5 (40.9 to 60.0)	39.4 (33.8 to 45.3)	20.0 (15.2 to 25.9)	39.7 (29.6 to 50.8)

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Maintaining a Health Assessment Questionnaire Disability Index (HAQ-DI) Improvement ≥0.3

End point title	Percentage of Participants Maintaining a Health Assessment Questionnaire Disability Index (HAQ-DI) Improvement ≥0.3

End point description:

The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty [0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.

An improvement of 0.22 or 0.3 points on the HAQ-DI has been identified as a minimal clinically important difference in Rheumatoid Arthritis participants.

APD: All enrolled participants who received at least one dose of study drug and completed at least 48 weeks in study JADY.

End point type	Secondary

End point timeframe:

Year 3 and Year 5 after entry into JADY

End point values	JADZ 4 mg Baricitinib	JADV 4 mg Baricitinib	JADX 2 mg Baricitinib	JADX 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	419	1034	169	366
Units: Percentage of participants				
number (confidence interval 95%)				
Year 1	85.4 (81.7 to 88.5)	75.6 (72.9 to 78.1)	72.8 (65.6 to 78.9)	69.4 (64.5 to 73.9)
Year 3	72.6 (68.1 to 76.6)	64.8 (61.8 to 67.6)	61.5 (54.0 to 68.5)	58.5 (53.4 to 63.4)
Year 5	62.8 (58.0 to 67.3)	53.4 (50.3 to 56.4)	46.7 (39.4 to 54.3)	46.2 (41.1 to 51.3)

End point values	JADW 2 mg Baricitinib	JADW 4 mg Baricitinib	JAGS 4 mg Baricitinib	JADA 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	101	274	210	78
Units: Percentage of participants				
number (confidence interval 95%)				
Year 1	65.3 (55.7 to 73.9)	61.7 (55.8 to 67.2)	75.2 (69.0 to 80.6)	43.6 (33.1 to 54.6)
Year 3	50.5 (40.9 to 60.0)	47.8 (42.0 to 53.7)	63.8 (57.1 to 70.0)	38.5 (28.4 to 49.6)
Year 5	46.5 (37.1 to 56.2)	35.0 (29.6 to 40.9)	19.5 (14.7 to 25.4)	34.6 (25.0 to 45.7)

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline of Originating Study in Bone Erosion Score

End point title	Change From Baseline of Originating Study in Bone Erosion Score

End point description:

The joint erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints of the feet. The maximum erosion score for a hand joint is 5 and for a foot joint is 10. Thus, the maximal erosion score is 280 for a timepoint (160 for both hands/ wrists and 120 for both feet). Each joint is scored according to the surface area involved from 0 to 5 for hand joints and 0 to 10 for the foot joints. The highest score (5 for the hand and 10 for the foot) indicates extensive loss of bone from more than one half of the articulating bone. A score of 0 in either the hand or foot joints indicates no erosion.

LSM was calculated using an MMRM model with treatment, baseline value, visit, and the interactions of baseline-by-visit and treatment-by-visit as fixed factors.

APD: All enrolled participants treated with at least 1 dose of study drug in JADY with available baseline (from originating study) and at least 1 postbaseline x-ray assessment (collected in JADY).

End point type	Secondary

End point timeframe:

Baseline, Year 1; Baseline, Year 3; Baseline, Year 5
N represents treatments arms consecutively which corresponds with listings in the header.
APD: JADW and JADA, zero participants analyzed due to no data collected in this study or originating study.

End point values	JADZ 4 mg Baricitinib	JADV 4 mg Baricitinib	JADX 2 mg Baricitinib	JADX 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	387[26]	943[27]	137[28]	301[29]
Units: Score on a sclae				
least squares mean (confidence interval 95%)				
Year 1: N=0, N=0, N=0, N=0, N=0, N=0, N=0, N=0, N=0	9999 (9999 to 9999)	9999 (9999 to 9999)	9999 (9999 to 9999)	9999 (9999 to 9999)
Year 3: N=387,N=943,N=137,N=301,N=0,N=0,	0.85 (0.63 to 1.08)	0.92 (0.76 to 1.07)	0.59 (0.30 to 0.89)	0.69 (0.49 to 0.89)
Year 5: N=349,N=870,N=127,N=276,N=0,N=0,	1.04 (0.77 to 1.32)	1.18 (0.98 to 1.38)	0.65 (0.28 to 1.01)	0.98 (0.74 to 1.23)

Notes:

[26] - 9999 = Data not available, zero participants analyzed.

[27] - 9999 = Data not available, zero participants analyzed.

[28] - 9999 = Data not available, zero participants analyzed.

[29] - 9999 = Data not available, zero participants analyzed.

End point values	JADW 2 mg Baricitinib	JADW 4 mg Baricitinib	JAGS 4 mg Baricitinib	JADA 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0[30]	0[31]	203	0[32]
Units: Score on a sclae				
least squares mean (confidence interval 95%)				
Year 1: N=0, N=0, N=0, N=0, N=0, N=0, N=0, N=0, N=0	(to)	(to)	0.00 (0.00 to 0.00)	(to)
Year 3: N=387,N=943,N=137,N=301,N=0,N=0,	(to)	(to)	0.68 (0.32 to 1.03)	(to)

Year 5: N=349,N=870,N=127,N=276,N=0,N=0,	(to)	(to)	9999 (9999 to 9999)	(to)

Notes:

[30] - No data collected; zero participants analyzed.

[31] - No data collected; zero participants analyzed.

[32] - No data collected; zero participants analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: Healthcare Resource Utilization

End point title	Healthcare Resource Utilization

End point description:

Healthcare resource utilization data will be collected by site staff regarding the number of visits to medical care providers such as general practitioners, specialists, physical or occupational therapists, and other nonphysical care providers for services outside of the clinical study; emergency room admissions; hospital admissions; and concomitant medications related to the treatment of Rheumatoid Arthritis (RA).

APD: All enrolled participants who received at least one dose of study drug, with access healthcare services outside of the clinical study.

End point type	Secondary

End point timeframe:

Baseline Up to 84 months

End point values	JADZ 4 mg Baricitinib	JADV 4 mg Baricitinib	JADX 2 mg Baricitinib	JADX 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	451	1090	180	403
Units: Consultations				
number (not applicable)				
Healthcare Consultations	3134	11108	2160	4573
Emergency Room Consultations	95	244	52	131

End point values	JADW 2 mg Baricitinib	JADW 4 mg Baricitinib	JAGS 4 mg Baricitinib	JADA 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	117	331	221	83
Units: Consultations				
number (not applicable)				
Healthcare Consultations	2380	5410	717	749
Emergency Room Consultations	73	154	40	16

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Maintaining a Simplified Disease Activity Index (SDAI) ≤11

End point title	Percentage of Participants Maintaining a Simplified Disease Activity Index (SDAI) ≤11

End point description:

SDAI is a tool for measurement of disease activity in RA that integrates TJC28, SJC28, acute phase response using C-reactive protein (milligrams per liter), Patient's Global Assessment of Disease Activity using VAS centimeters (cm), and Physician's Global Assessment of Disease Activity using VAS (cm). The SDAI is calculated by summing the values of the 5 components. Lower scores indicated less disease activity. An index-based definition of remission occurs with an SDAI score ≤3.3.

APD: All enrolled participants who received at least one dose of study drug and completed at least 48 weeks in study JADY.

End point type	Secondary

End point timeframe:

Year 1, Year 3, and Year 5 after entry in to JADY

End point values	JADZ 4 mg Baricitinib	JADV 4 mg Baricitinib	JADX 2 mg Baricitinib	JADX 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	419	1034	169	366
Units: Percentage of participants				
number (confidence interval 95%)				
Year 1	81.6 (77.6 to 85.0)	75.2 (72.5 to 77.8)	70.4 (63.1 to 76.8)	69.1 (64.2 to 73.6)
Year 3	73.3 (68.8 to 77.3)	67.8 (64.9 to 70.6)	60.9 (53.4 to 68.0)	62.3 (57.2 to 67.1)
Year 5	61.3 (56.6 to 65.9)	61.2 (58.2 to 64.1)	51.5 (44.0 to 58.9)	53.3 (48.2 to 58.3)

End point values	JADW 2 mg Baricitinib	JADW 4 mg Baricitinib	JAGS 4 mg Baricitinib	JADA 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	101	274	210	78
Units: Percentage of participants				
number (confidence interval 95%)				
Year 1	53.5 (43.8 to 62.9)	53.6 (47.7 to 59.5)	72.4 (66.0 to 78.0)	59.0 (47.9 to 69.2)
Year 3	48.5 (39.0 to 58.1)	44.5 (38.8 to 50.4)	60.0 (53.3 to 66.4)	57.7 (46.6 to 68.0)
Year 5	46.5 (37.1 to 56.2)	35.4 (30.0 to 41.2)	23.3 (18.1 to 29.5)	57.7 (46.6 to 68.0)

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Maintaining a Simplified Disease Activity Index (SDAI) ≤3.3

End point title	Percentage of Participants Maintaining a Simplified Disease Activity Index (SDAI) ≤3.3

End point description:

SDAI is a tool for measurement of disease activity in RA that integrates TJC28, SJC28, acute phase response using C-reactive protein (milligrams per liter), Patient's Global Assessment of Disease Activity using VAS centimeters (cm), and Physician's Global Assessment of Disease Activity using VAS (cm). The SDAI is calculated by summing the values of the 5 components. Lower scores indicated less disease activity. An index-based definition of remission occurs with an SDAI score ≤3.3.

APD: All enrolled participants who received at least one dose of study drug and completed at least 48 weeks in study JADY.

End point type	Secondary

End point timeframe:

Year 1, Year 3 and Year 5

End point values	JADZ 4 mg Baricitinib	JADV 4 mg Baricitinib	JADX 2 mg Baricitinib	JADX 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	419	1034	169	366
Units: Percentage of participants				
number (confidence interval 95%)				
Year 1	45.3 (40.6 to 50.1)	28.9 (26.2 to 31.8)	24.3 (18.4 to 31.2)	23.5 (19.4 to 28.1)
Year 3	39.9 (35.3 to 44.6)	29.8 (27.1 to 32.6)	22.5 (16.8 to 29.4)	21.6 (17.7 to 26.1)
Year 5	34.8 (30.4 to 39.5)	24.7 (22.1 to 27.4)	20.7 (15.3 to 27.4)	21.3 (17.4 to 25.8)

End point values	JADW 2 mg Baricitinib	JADW 4 mg Baricitinib	JAGS 4 mg Baricitinib	JADA 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	101	274	210	78
Units: Percentage of participants				
number (confidence interval 95%)				
Year 1	13.9 (8.4 to 21.9)	13.1 (9.6 to 17.7)	22.9 (17.7 to 29.0)	14.1 (8.1 to 23.5)
Year 3	19.8 (13.2 to 28.6)	13.5 (10.0 to 18.1)	15.7 (11.4 to 21.2)	21.8 (14.1 to 32.2)
Year 5	13.9 (8.4 to 21.9)	11.3 (8.1 to 15.6)	8.1 (5.1 to 12.6)	21.8 (14.1 to 32.2)

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants with Relapse Event During the 96-Week Step-Down Period

End point title	Percentage of Participants with Relapse Event During the 96-Week Step-Down Period

End point description:

Relapse is defined as CDAI score > 10 in participants originating from JADV, JADW,JADX and JAGS. The time point refers to time to relapse in the step-down period.

APD: All enrolled participants who were randomized, were not rescued, and received at least one dose of study drug during the step-down period.

End point type	Secondary

End point timeframe:

Week 0 through Week 96 of Step-down

End point values	2 mg Baricitinib Step-down	4 mg Baricitinib Step-down		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	498	498		
Units: Percentage of participants				
number (not applicable)				
Week 12	11.8	5.4		
Week 24	26.0	12.5		
Week 36	31.0	18.2		
Week 48	36.0	21.1		
Week 60	41.0	26.6		
Week 72	45.1	29.1		
Week 84	46.7	31.0		
Week 96	47.8	34.5		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Maintaining a DAS28-Erythrocyte Sedimentation Rate (ESR) Score of ≤3.2

End point title	Percentage of Participants Maintaining a DAS28-Erythrocyte Sedimentation Rate (ESR) Score of ≤3.2

End point description:

DAS28 consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), ESR (millimeters per hour), and Patient's Global Assessment of Disease Activity. DAS28 was calculated using following formula: DAS28-ESR=0.56*square root (sqrt)(TJC28)+0.28*sqrt(SJC28)+0.70*natural log(ESR)+0.014*Patient's Global VAS. Total scores ranged from 1.0-9.4, where lower scores indicated less disease activity.

APD: All enrolled participants who received at least one dose of study drug and completed at least 48 weeks in study JADY.

End point type	Secondary

End point timeframe:

Year 1, 3, and 5 after entry into JADY

End point values	JADZ 4 mg Baricitinib	JADV 4 mg Baricitinib	JADX 2 mg Baricitinib	JADX 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	419	1034	169	366
Units: Percentage of participants				
number (confidence interval 95%)				
Year 1	61.8 (57.1 to 66.3)	48.4 (45.3 to 51.4)	46.2 (38.8 to 53.7)	48.4 (43.3 to 53.5)
Year 3	54.4 (49.6 to 59.1)	46.1 (43.1 to 49.2)	40.2 (33.1 to 47.8)	41.0 (36.1 to 46.1)
Year 5	48.7 (43.9 to 53.5)	41.3 (38.3 to 44.3)	36.1 (29.2 to 43.6)	32.5 (27.9 to 37.5)

End point values	JADW 2 mg Baricitinib	JADW 4 mg Baricitinib	JAGS 4 mg Baricitinib	JADA 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	101	274	210	78
Units: Percentage of participants				
number (confidence interval 95%)				
Year 1	31.7 (23.4 to 41.3)	31.8 (26.5 to 37.5)	41.0 (34.5 to 47.7)	35.9 (26.1 to 47.0)
Year 3	22.8 (15.7 to 31.9)	23.7 (19.1 to 29.1)	33.8 (27.8 to 40.4)	37.2 (27.3 to 48.3)
Year 5	23.8 (16.5 to 32.9)	21.9 (17.4 to 27.2)	11.4 (7.8 to 16.4)	37.2 (27.3 to 48.3)

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Maintaining a DAS28-Erythrocyte Sedimentation Rate (ESR) Sore of <2.6

End point title	Percentage of Participants Maintaining a DAS28-Erythrocyte Sedimentation Rate (ESR) Sore of <2.6

End point description:

DAS28 consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), ESR (millimeters per hour), and Patient's Global Assessment of Disease Activity. DAS28 was calculated using following formula: DAS28-ESR=0.56*square root (sqrt)(TJC28)+0.28*sqrt(SJC28)+0.70*natural log(ESR)+0.014*Patient's Global VAS. Total scores ranged from 1.0-9.4, where lower scores indicated less disease activity.

APD: All enrolled participants who received at least one dose of study drug and completed at least 48 weeks in study JADY.

End point type	Secondary

End point timeframe:

Year 1, 3, and 5 after entry into JADY

End point values	JADZ 4 mg Baricitinib	JADV 4 mg Baricitinib	JADX 2 mg Baricitinib	JADX 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	419	1034	169	366
Units: Percentage of participants				
number (confidence interval 95%)				
Year 1	36.8 (32.3 to 41.5)	29.3 (26.6 to 32.2)	24.3 (18.4 to 31.2)	26.8 (22.5 to 31.5)
Year 3	38.9 (34.4 to 43.7)	24.7 (22.1 to 27.4)	24.3 (18.4 to 31.2)	23.2 (19.2 to 27.8)
Year 5	31.3 (27.0 to 35.9)	23.9 (21.4 to 26.6)	22.5 (16.8 to 29.4)	19.4 (15.7 to 23.8)

End point values	JADW 2 mg Baricitinib	JADW 4 mg Baricitinib	JAGS 4 mg Baricitinib	JADA 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	101	241	210	78
Units: Percentage of participants				
number (confidence interval 95%)				
Year 1	20.8 (14.0 to 29.7)	13.1 (9.6 to 17.7)	25.2 (19.8 to 31.5)	15.4 (9.0 to 25.0)
Year 3	15.8 (10.0 to 24.2)	10.2 (7.2 to 14.4)	19.5 (14.7 to 25.4)	23.1 (15.1 to 33.6)
Year 5	11.9 (6.9 to 19.6)	8.8 (6.0 to 12.7)	7.1 (4.4 to 11.4)	19.2 (12.0 to 29.3)

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline of Originating Study in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Scores (Self-Perceived Health)

End point title	Change From Baseline of Originating Study in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Scores (Self-Perceived Health)

End point description:

The European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. The second component is a self-perceived health score which is assessed using a VAS that ranged from 0 to 100 millimeter (mm), where 0 mm indicated the worst health you can imagine and 100 mm indicated the best health you can imagine.

APD: All enrolled participants who received at least 1 dose of study drug and completed at least 48 weeks in study JADY. EQ-5D-5L data was not collected during the JADA originating study, zero participants analyzed.

End point type	Secondary

End point timeframe:

Baseline, Year 1; Baseline, Year 3; Baseline, Year 5

End point values	JADZ 4 mg Baricitinib	JADV 4 mg Baricitinib	JADX 2 mg Baricitinib	JADX 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	450	1088	171	383
Units: millimeter(s)				
arithmetic mean (standard deviation)				
Yr1:N=450,N=1088,N=171,N=383,N=108,N=305,N=221,N=0	24.69 (± 28.50)	19.72 (± 28.17)	15.13 (± 26.78)	18.32 (± 26.35)
Yr3:N=386,N=952,N=146,N=309,N=80,N=219,N=190,N=0	28.48 (± 29.88)	22.10 (± 28.02)	16.29 (± 25.37)	16.48 (± 30.24)
Yr5:N=330,N=820,N=122,N=264,N=70,N=169,N=127,N=0	31.13 (± 28.15)	23.93 (± 28.45)	13.82 (± 25.59)	19.34 (± 27.48)

End point values	JADW 2 mg Baricitinib	JADW 4 mg Baricitinib	JAGS 4 mg Baricitinib	JADA 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	108	305	221	0[33]
Units: millimeter(s)				
arithmetic mean (standard deviation)				
Yr1:N=450,N=1088,N=171,N=383,N=108,N=305,N=221,N=0	20.96 (± 24.53)	14.98 (± 30.21)	18.47 (± 27.31)	()
Yr3:N=386,N=952,N=146,N=309,N=80,N=219,N=190,N=0	23.53 (± 24.70)	18.79 (± 30.03)	21.45 (± 29.64)	()
Yr5:N=330,N=820,N=122,N=264,N=70,N=169,N=127,N=0	26.19 (± 27.09)	23.57 (± 31.67)	27.31 (± 27.19)	()

Notes:

[33] - Zero participants analyzed; data not collected.

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Baseline up to 84 months.

Adverse event reporting additional description:

All enrolled participants who received at least 1 dose of study drug and did not discontinue the study for the reason 'Lost to Follow-up' at the first postbaseline visit in study JADY.

Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	23.1

Reporting groups

Reporting group title	2 mg Baricitinib

Reporting group description:

2 mg Baricitinib administered orally once daily throughout the 84-month treatment period.

Reporting group title	4 mg Baricitinib

Reporting group description:

4 mg Baricitinib administered orally once daily throughout the 84-month treatment period.

Reporting group title	2 mg Baricitinib Step-Down

Reporting group description:

2 mg Baricitinib administered orally once daily throughout the 96-week step-down period.

Reporting group title	4 mg Baricitinib Step-Down

Reporting group description:

4 mg Baricitinib administered orally once daily throughout the 96-week step-down period.

Serious adverse events	2 mg Baricitinib	4 mg Baricitinib	2 mg Baricitinib Step-Down
Total subjects affected by serious adverse events			
subjects affected / exposed	112 / 297 (37.71%)	517 / 2579 (20.05%)	164 / 592 (27.70%)
number of deaths (all causes)	7	43	14
number of deaths resulting from adverse events	1	11	4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
adenocarcinoma of colon			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
adenocarcinoma pancreas			

alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
anaplastic meningioma			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
angiolipoma			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
basal cell carcinoma			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
benign neoplasm of skin			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
benign neoplasm of thyroid gland			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
bladder cancer			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	1 / 297 (0.34%)	1 / 2579 (0.04%)	2 / 592 (0.34%)
occurrences causally related to treatment / all	0 / 1	0 / 1	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
bowen's disease			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
brain neoplasm			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
breast cancer			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	1 / 2	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
breast cancer metastatic			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	3 / 2579 (0.12%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	2 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
cervix carcinoma			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed[1]	0 / 231 (0.00%)	1 / 2031 (0.05%)	1 / 440 (0.23%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cervix carcinoma stage 0			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed[2]	0 / 231 (0.00%)	1 / 2031 (0.05%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

clear cell renal cell carcinoma alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
colon adenoma alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
colon cancer alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
colorectal cancer stage iv alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
diffuse large b-cell lymphoma alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	4 / 2579 (0.16%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	3 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
extranodal marginal zone b-cell lymphoma (malt type) alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
fibrous histiocytoma alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
gallbladder cancer			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
gastric cancer			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	1 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
gastric neoplasm			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
giant cell tumour of tendon sheath			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
intraductal proliferative breast lesion			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
invasive ductal breast carcinoma			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	2 / 297 (0.67%)	4 / 2579 (0.16%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	2 / 2	1 / 4	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

large granular lymphocytosis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	3 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
large intestine fibroma			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
laryngeal cancer			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
lentigo maligna			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
leukaemia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
lipoma			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	4 / 2579 (0.16%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 5	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
lung adenocarcinoma			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	1 / 297 (0.34%)	3 / 2579 (0.12%)	2 / 592 (0.34%)
occurrences causally related to treatment / all	0 / 1	0 / 4	1 / 2
deaths causally related to treatment / all	0 / 1	0 / 2	0 / 0
lung adenocarcinoma stage iv			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
lung cancer metastatic			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
lung neoplasm			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
lung neoplasm malignant			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	3 / 2579 (0.12%)	2 / 592 (0.34%)
occurrences causally related to treatment / all	0 / 1	1 / 3	1 / 2
deaths causally related to treatment / all	0 / 0	1 / 1	1 / 2
lung squamous cell carcinoma metastatic			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
lymphocytic leukaemia			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
lymphoproliferative disorder			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	2 / 592 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 1	3 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
malignant fibrous histiocytoma			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
malignant glioma			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
malignant melanoma			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
malignant melanoma in situ			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
malignant peritoneal neoplasm			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

malignant pleural effusion			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
meningioma			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
metastases to central nervous system			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
metastases to peritoneum			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
metastatic gastric cancer			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
mucoepidermoid carcinoma			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
mueller's mixed tumour			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed[3]	0 / 231 (0.00%)	1 / 2031 (0.05%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
neoplasm malignant			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
neuroendocrine carcinoma of the skin			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
non-hodgkin's lymphoma			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
non-small cell lung cancer metastatic			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
nonkeratinising carcinoma of nasopharynx			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	1 / 1	0 / 0	0 / 0
oesophageal squamous cell carcinoma			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
oral neoplasm benign			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ovarian adenoma			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed[4]	0 / 231 (0.00%)	1 / 2031 (0.05%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ovarian cancer			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed[5]	1 / 231 (0.43%)	2 / 2031 (0.10%)	0 / 440 (0.00%)
occurrences causally related to treatment / all	0 / 1	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ovarian cancer stage iv			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed[6]	0 / 231 (0.00%)	1 / 2031 (0.05%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ovarian germ cell teratoma benign			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed[7]	1 / 231 (0.43%)	0 / 2031 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
paget's disease of nipple			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

pancreatic carcinoma			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
pancreatic carcinoma metastatic			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pancreatic carcinoma stage iv			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
papillary cystadenoma lymphomatosum			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
papillary thyroid cancer			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
prostate cancer			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed[8]	1 / 66 (1.52%)	3 / 548 (0.55%)	2 / 152 (1.32%)
occurrences causally related to treatment / all	0 / 2	1 / 3	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
prostate cancer metastatic			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed[9]	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 152 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
prostatic adenoma			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed[10]	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 152 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
rectal cancer			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
renal cancer			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
renal cell carcinoma			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
skin cancer			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
small cell lung cancer metastatic			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1

squamous cell carcinoma			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
squamous cell carcinoma of lung			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
squamous cell carcinoma of skin			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
squamous cell carcinoma of the cervix			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed[11]	0 / 231 (0.00%)	1 / 2031 (0.05%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
squamous cell carcinoma of the parotid gland			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
t-cell lymphoma			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
thyroid cancer stage i			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
uterine cancer			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed[12]	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 440 (0.23%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
uterine carcinoma in situ			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed[13]	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 440 (0.23%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
uterine leiomyoma			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed[14]	0 / 231 (0.00%)	2 / 2031 (0.10%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
aortic arteriosclerosis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
deep vein thrombosis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	4 / 297 (1.35%)	14 / 2579 (0.54%)	2 / 592 (0.34%)
occurrences causally related to treatment / all	0 / 4	5 / 16	2 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
embolism arterial			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
essential hypertension			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
haematoma			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	2 / 297 (0.67%)	3 / 2579 (0.12%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 5	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
haemorrhage			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
hypertension			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
hypertensive crisis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
hypotension			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

hypovolaemic shock			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
intermittent claudication			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
jugular vein thrombosis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
necrosis ischaemic			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
peripheral artery stenosis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
peripheral ischaemia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
peripheral venous disease			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
rheumatoid vasculitis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
thrombophlebitis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
thrombosed varicose vein			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
varicose vein			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
vasculitis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
venous thrombosis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

venous thrombosis limb			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
arthrodesis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cataract operation			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
finger amputation			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
hysterectomy			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed[15]	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 440 (0.23%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
internal fixation of fracture			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
joint arthroplasty			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
knee arthroplasty			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	2 / 297 (0.67%)	3 / 2579 (0.12%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
limb reconstructive surgery			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
rehabilitation therapy			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
scar excision			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
shoulder arthroplasty			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
vaginal cyst excision			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed[16]	0 / 231 (0.00%)	1 / 2031 (0.05%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pregnancy, puerperium and perinatal conditions			
abortion spontaneous			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed[17]	1 / 231 (0.43%)	2 / 2031 (0.10%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	1 / 1	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pregnancy			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed[18]	0 / 231 (0.00%)	1 / 2031 (0.05%)	1 / 440 (0.23%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
adverse drug reaction			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
alcohol interaction			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
chest pain			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	3 / 2579 (0.12%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
complication associated with device			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
death			

alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	2 / 2579 (0.08%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 2	0 / 0
exercise tolerance decreased			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
general physical health deterioration			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
mucosal inflammation			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
multiple organ dysfunction syndrome			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
non-cardiac chest pain			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	2 / 297 (0.67%)	2 / 2579 (0.08%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pain			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pyrexia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	2 / 297 (0.67%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	2 / 4	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
sudden cardiac death			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
systemic inflammatory response syndrome			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
anaphylactic reaction			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
hypersensitivity			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Social circumstances			
respite care			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
adnexa uteri cyst			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed[19]	0 / 231 (0.00%)	2 / 2031 (0.10%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
bartholin's cyst			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed[20]	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 440 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
benign prostatic hyperplasia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed[21]	0 / 66 (0.00%)	1 / 548 (0.18%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cervical cyst			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed[22]	0 / 231 (0.00%)	1 / 2031 (0.05%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cervical dysplasia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed[23]	0 / 297 (0.00%)	0 / 2579 (0.00%)	2 / 440 (0.45%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
dysfunctional uterine bleeding			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed[24]	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 440 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
endometrial hyperplasia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed[25]	0 / 231 (0.00%)	1 / 2031 (0.05%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
endometrial hypertrophy			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed[26]	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 440 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
endometriosis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed[27]	0 / 231 (0.00%)	1 / 2031 (0.05%)	2 / 440 (0.45%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
genital prolapse			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
metrorrhagia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed[28]	0 / 231 (0.00%)	4 / 2031 (0.20%)	0 / 440 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 5	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ovarian cyst			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed[29]	0 / 231 (0.00%)	3 / 2031 (0.15%)	0 / 440 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

pelvic pain			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
testicular cyst			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed[30]	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 152 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
uterine polyp			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed[31]	0 / 231 (0.00%)	1 / 2031 (0.05%)	0 / 440 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
uterine prolapse			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed[32]	1 / 231 (0.43%)	0 / 2031 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
vaginal haemorrhage			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed[33]	1 / 231 (0.43%)	0 / 2031 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
vaginal prolapse			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed[34]	0 / 231 (0.00%)	1 / 2031 (0.05%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
acute pulmonary oedema			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	1 / 297 (0.34%)	2 / 2579 (0.08%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	1 / 1	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
acute respiratory distress syndrome			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
acute respiratory failure			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	5 / 2579 (0.19%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 5	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
allergic bronchitis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
asthma			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	4 / 2579 (0.16%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
atelectasis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
bronchitis chronic			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

bronchopneumopathy			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
bronchospasm			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
chronic obstructive pulmonary disease			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	9 / 2579 (0.35%)	2 / 592 (0.34%)
occurrences causally related to treatment / all	3 / 3	2 / 17	0 / 11
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
cough			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
interstitial lung disease			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	5 / 2579 (0.19%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	3 / 6	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
lung disorder			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
nasal polyps			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
obstructive airways disorder			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
organising pneumonia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	3 / 2579 (0.12%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pleural effusion			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	3 / 2579 (0.12%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	1 / 1	1 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pleurisy			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pneumonia aspiration			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	1 / 2579 (0.04%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
pneumonitis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

pneumothorax			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pulmonary arterial hypertension			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pulmonary embolism			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	5 / 297 (1.68%)	18 / 2579 (0.70%)	5 / 592 (0.84%)
occurrences causally related to treatment / all	4 / 8	6 / 21	1 / 5
deaths causally related to treatment / all	0 / 0	1 / 2	0 / 2
pulmonary hypertension			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pulmonary mass			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pulmonary oedema			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
respiratory arrest			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
respiratory failure			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	6 / 2579 (0.23%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	1 / 7	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
sleep apnoea syndrome			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
vocal cord polyp			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
anxiety			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
confusional state			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
depressed mood			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
depression			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	3 / 2579 (0.12%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 5	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
mental disorder			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
mental status changes			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
suicidal ideation			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
suicide attempt			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Product issues			
device dislocation			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
device failure			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
device loosening			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	3 / 2579 (0.12%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
bile duct stone			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
biliary colic			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
biliary obstruction			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cholangitis			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	1 / 2	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cholecystitis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	2 / 297 (0.67%)	4 / 2579 (0.16%)	3 / 592 (0.51%)
occurrences causally related to treatment / all	0 / 2	2 / 5	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cholecystitis acute			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	4 / 2579 (0.16%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cholecystitis chronic			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cholelithiasis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	8 / 2579 (0.31%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 9	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
gallbladder polyp			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
hepatic cirrhosis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

liver disorder			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
nonalcoholic fatty liver disease			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
blood creatine phosphokinase increased			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	2 / 592 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
blood glucose increased			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
blood pressure increased			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cardiac murmur			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
electrocardiogram t wave inversion			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
electrocardiogram change			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
glomerular filtration rate decreased			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
haemoglobin decreased			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
influenza a virus test positive			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
mycobacterium tuberculosis complex test positive			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
transaminases increased			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
accident			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ankle fracture			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
brain herniation			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
burns second degree			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
carbon monoxide poisoning			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cervical vertebral fracture			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
colon injury			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
compression fracture			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
contusion			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
crush injury			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
dislocation of vertebra			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
epiphyseal injury			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

face injury alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
fall alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	2 / 297 (0.67%)	13 / 2579 (0.50%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	1 / 2	0 / 14	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
femoral neck fracture alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	1 / 2579 (0.04%)	2 / 592 (0.34%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
femur fracture alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	7 / 2579 (0.27%)	3 / 592 (0.51%)
occurrences causally related to treatment / all	0 / 0	1 / 8	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
fibula fracture alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
foot fracture alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	3 / 2579 (0.12%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
hand fracture alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
head injury			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
hip fracture			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	5 / 2579 (0.19%)	2 / 592 (0.34%)
occurrences causally related to treatment / all	0 / 1	0 / 5	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
humerus fracture			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	3 / 2579 (0.12%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 4	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
injury			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
joint dislocation			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	3 / 2579 (0.12%)	2 / 592 (0.34%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
joint injury			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

keratorhexis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ligament rupture			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
lower limb fracture			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	3 / 2579 (0.12%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
lumbar vertebral fracture			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	2 / 2579 (0.08%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
meniscus injury			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	7 / 2579 (0.27%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 7	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
open globe injury			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
open fracture			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
overdose			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
patella fracture			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pelvic fracture			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
periprosthetic fracture			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
post procedural complication			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
post procedural haematoma			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

post procedural haemorrhage alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
radius fracture alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
rib fracture alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
road traffic accident alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	3 / 2579 (0.12%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
scapula fracture alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
seroma alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
skin wound alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
skull fracture			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
spinal compression fracture			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	6 / 2579 (0.23%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 1	0 / 6	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
suture rupture			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
synovial rupture			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
tendon injury			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
tendon rupture			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	2 / 592 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

thoracic vertebral fracture alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
tibia fracture alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	3 / 2579 (0.12%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
toxicity to various agents alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
traumatic arthritis alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
upper limb fracture alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
wound alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
wound dehiscence alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
wrist fracture			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
congenital central nervous system anomaly			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
hydrocele			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed[35]	0 / 66 (0.00%)	1 / 548 (0.18%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
hypertrophic cardiomyopathy			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
acute coronary syndrome			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
acute left ventricular failure			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
acute myocardial infarction			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	4 / 297 (1.35%)	7 / 2579 (0.27%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	2 / 5	1 / 7	1 / 1
deaths causally related to treatment / all	0 / 1	0 / 2	0 / 0
angina pectoris			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	3 / 2579 (0.12%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 1	1 / 3	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
angina unstable			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	5 / 2579 (0.19%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	1 / 1	2 / 5	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
aortic valve disease			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
aortic valve incompetence			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
aortic valve stenosis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

arteriosclerosis coronary artery alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
atrial fibrillation alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	4 / 297 (1.35%)	11 / 2579 (0.43%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 5	4 / 13	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
atrial tachycardia alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
atrioventricular block complete alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
bradycardia alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
bundle branch block left alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cardiac arrest alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 297 (0.00%)	4 / 2579 (0.16%)	2 / 592 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 4	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 2	0 / 1
cardiac failure			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	1 / 2579 (0.04%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 3	0 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
cardiac failure acute			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cardiac failure chronic			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cardiac failure congestive			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	3 / 297 (1.01%)	4 / 2579 (0.16%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	1 / 3	0 / 4	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cardio-respiratory arrest			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 2	0 / 1
chronic left ventricular failure			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

coronary artery disease			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	3 / 2579 (0.12%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 6	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
coronary artery occlusion			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
coronary artery stenosis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
mitral valve disease			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
mitral valve incompetence			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
myocardial infarction			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	4 / 2579 (0.16%)	2 / 592 (0.34%)
occurrences causally related to treatment / all	0 / 0	3 / 6	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
myocardial ischaemia			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	2 / 592 (0.34%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
palpitations			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pericarditis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
right ventricular failure			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
sinus node dysfunction			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
sinus tachycardia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
stress cardiomyopathy			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

supraventricular tachycardia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ventricular arrhythmia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ventricular fibrillation			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ventricular tachycardia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
amyotrophic lateral sclerosis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
autonomic neuropathy			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
basal ganglia haemorrhage			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
central nervous system vasculitis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cerebellar infarction			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cerebellar stroke			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cerebral artery stenosis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cerebral artery thrombosis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cerebral haemorrhage			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

cerebral infarction alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cerebral microhaemorrhage alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cerebral thrombosis alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cerebral venous thrombosis alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cerebrospinal fistula alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cerebrovascular accident alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cerebrospinal fluid leakage alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cerebrovascular disorder			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cervical cord compression			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cervical radiculopathy			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
dementia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
depressed level of consciousness			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
dizziness			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

embolic stroke			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
epilepsy			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
haemorrhage intracranial			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
haemorrhagic stroke			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	5 / 2579 (0.19%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 5	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
headache			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	1 / 2579 (0.04%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
hemiparesis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
intercostal neuralgia			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
intracranial aneurysm			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ischaemic cerebral infarction			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ischaemic stroke			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	5 / 297 (1.68%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 7	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
leukoencephalopathy			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
loss of consciousness			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
metabolic encephalopathy			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

migraine alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
myelopathy alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	2 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
neuralgia alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
neuropathy peripheral alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
peripheral sensorimotor neuropathy alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
post herpetic neuralgia alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
presyncope alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
radiculopathy			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
sciatica			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	3 / 2579 (0.12%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
seizure			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
sensory disturbance			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
subarachnoid haemorrhage			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
syncope			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	9 / 2579 (0.35%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 10	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

thalamus haemorrhage			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
transient ischaemic attack			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	4 / 2579 (0.16%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
anaemia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	2 / 297 (0.67%)	3 / 2579 (0.12%)	2 / 592 (0.34%)
occurrences causally related to treatment / all	1 / 2	3 / 4	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
coagulopathy			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
febrile neutropenia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
leukocytosis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
lymphopenia			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
normochromic normocytic anaemia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
normocytic anaemia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pancytopenia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	3 / 2579 (0.12%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
thrombocytopenia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
thrombocytosis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
conductive deafness			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
deafness unilateral			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
meniere's disease			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
sudden hearing loss			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
vertigo			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
vertigo positional			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
cataract			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	1 / 297 (0.34%)	6 / 2579 (0.23%)	3 / 592 (0.51%)
occurrences causally related to treatment / all	0 / 1	2 / 13	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cataract subcapsular			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
corneal perforation			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
dry age-related macular degeneration			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
glaucoma			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
keratitis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
macular rupture			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ocular hypertension			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
retinal detachment			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
rhegmatogenous retinal detachment			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
abdominal pain			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	2 / 2579 (0.08%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
abdominal pain upper			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
abdominal wall haematoma			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
anal fistula			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
colitis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	3 / 2579 (0.12%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	2 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
colitis ischaemic			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
colitis ulcerative			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
dental cyst			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
diarrhoea			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

diverticular perforation alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	1 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
diverticulum alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
diverticulum intestinal alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
duodenal ulcer haemorrhage alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
duodenitis alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
dysphagia alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
enterocolitis alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	2 / 592 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
gastric ulcer			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	3 / 2579 (0.12%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
gastric ulcer haemorrhage			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
gastric ulcer perforation			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
gastritis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 2	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
gastritis erosive			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
gastrointestinal haemorrhage			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	3 / 2579 (0.12%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	1 / 1	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0

gastrooesophageal reflux disease alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
haemorrhoids alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
hiatus hernia alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ileus alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
inguinal hernia alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
intestinal obstruction alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
intestinal perforation alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
irritable bowel syndrome			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
obstructive pancreatitis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
oesophageal stenosis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pancreatitis acute			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	6 / 2579 (0.23%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	1 / 7	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
parotid gland enlargement			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
rectal haemorrhage			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

rectal polyp			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
reflux gastritis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
small intestinal obstruction			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 5	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
umbilical hernia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
upper gastrointestinal haemorrhage			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	2 / 2579 (0.08%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	1 / 1	1 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
volvulus			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
vomiting			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	1 / 297 (0.34%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
actinic keratosis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
angioedema			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
diabetic ulcer			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
eczema asteatotic			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
granuloma skin			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
skin necrosis			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
skin ulcer			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
acute kidney injury			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	4 / 2579 (0.16%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	1 / 3	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
bladder prolapse			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
calculus bladder			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
calculus urinary			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
chronic kidney disease			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
glomerulonephritis membranous			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
hydronephrosis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	3 / 2579 (0.12%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
iga nephropathy			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
nephrolithiasis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	2 / 297 (0.67%)	5 / 2579 (0.19%)	3 / 592 (0.51%)
occurrences causally related to treatment / all	0 / 2	0 / 5	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
oliguria			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
proteinuria			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

renal colic			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
renal cyst			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
renal injury			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
renal pain			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
renal vein thrombosis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
stress urinary incontinence			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
tubulointerstitial nephritis			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ureterolithiasis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	6 / 2579 (0.23%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 7	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
urinary tract inflammation			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
adrenal suppression			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
goitre			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
hyperparathyroidism			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
acquired claw toe			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
arthralgia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	2 / 297 (0.67%)	2 / 2579 (0.08%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
arthritis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	3 / 2579 (0.12%)	2 / 592 (0.34%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
back pain			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	5 / 2579 (0.19%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 1	0 / 8	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cervical spinal stenosis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	2 / 592 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
chondrocalcinosis pyrophosphate			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
diastasis recti abdominis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

foot deformity			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	4 / 2579 (0.16%)	3 / 592 (0.51%)
occurrences causally related to treatment / all	0 / 2	0 / 5	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
fracture delayed union			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
haematoma muscle			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
intervertebral disc compression			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
intervertebral disc degeneration			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
intervertebral disc disorder			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
intervertebral disc protrusion			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	1 / 297 (0.34%)	7 / 2579 (0.27%)	5 / 592 (0.84%)
occurrences causally related to treatment / all	0 / 1	0 / 7	0 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
joint destruction			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
lumbar spinal stenosis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	4 / 2579 (0.16%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 2	0 / 5	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
mixed connective tissue disease			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
muscular weakness			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
musculoskeletal chest pain			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
osteoarthritis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	8 / 297 (2.69%)	42 / 2579 (1.63%)	6 / 592 (1.01%)
occurrences causally related to treatment / all	0 / 13	4 / 56	0 / 9
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

osteochondrosis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
osteonecrosis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	2 / 2579 (0.08%)	2 / 592 (0.34%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
osteoporosis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
osteoporotic fracture			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pain in extremity			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
rhabdomyolysis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
rheumatoid arthritis			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	4 / 297 (1.35%)	16 / 2579 (0.62%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 6	1 / 18	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
rheumatoid nodule			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
rotator cuff syndrome			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
scoliosis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
spinal instability			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
spinal osteoarthritis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
spinal pain			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	2 / 2579 (0.08%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

spinal stenosis alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	3 / 2579 (0.12%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 6	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
spondyloarthropathy alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
spondylolisthesis alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
synovial cyst alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
synovitis alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
tendonitis alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
tenosynovitis alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
abdominal infection			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
abdominal wall abscess			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
abscess intestinal			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
abscess limb			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
anal abscess			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
appendicitis			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	2 / 297 (0.67%)	3 / 2579 (0.12%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 2	1 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
appendicitis perforated			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
arthritis bacterial			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	3 / 2579 (0.12%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	1 / 1	2 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
arthritis infective			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
atypical pneumonia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	3 / 2579 (0.12%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
bacteraemia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
bacterial infection			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

bone tuberculosis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	3 / 2579 (0.12%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
breast abscess			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
bronchitis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	5 / 2579 (0.19%)	2 / 592 (0.34%)
occurrences causally related to treatment / all	0 / 1	3 / 6	3 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
bronchitis viral			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
bursitis infective			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
bursitis infective staphylococcal			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
covid-19			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	2 / 592 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
covid-19 pneumonia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cellulitis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	3 / 297 (1.01%)	12 / 2579 (0.47%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	2 / 3	7 / 14	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cholecystitis infective			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
chronic sinusitis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
chronic tonsillitis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
coronavirus infection			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0

cystitis alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	2 / 2579 (0.08%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	1 / 1	2 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cytomegalovirus hepatitis alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cytomegalovirus infection alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
dengue fever alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
device related infection alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	4 / 2579 (0.16%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	2 / 5	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
device related sepsis alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
disseminated tuberculosis alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 297 (0.00%)	3 / 2579 (0.12%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	3 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
diverticulitis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	3 / 297 (1.01%)	4 / 2579 (0.16%)	3 / 592 (0.51%)
occurrences causally related to treatment / all	1 / 3	2 / 4	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
empyema			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
encephalitis viral			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
endocarditis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
endocarditis bacterial			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
enteritis infectious			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

enterobacter pneumonia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
enterocolitis infectious			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
erysipelas			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
escherichia sepsis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
extrapulmonary tuberculosis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
fascial infection			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
gangrene			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
gastroenteritis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	7 / 2579 (0.27%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	1 / 1	2 / 7	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
gastroenteritis norovirus			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
gastroenteritis salmonella			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
gastroenteritis viral			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
groin abscess			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
h1n1 influenza			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

haematoma infection			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
helicobacter gastritis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
hepatitis e			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
herpes zoster			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	5 / 297 (1.68%)	15 / 2579 (0.58%)	2 / 592 (0.34%)
occurrences causally related to treatment / all	4 / 5	20 / 20	3 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
herpes zoster infection neurological			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
herpes zoster meningitis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
histoplasmosis			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
implant site infection			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
incision site cellulitis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
infected dermal cyst			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
infected skin ulcer			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	1 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
infection			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
infectious pleural effusion			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	3 / 3	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

infective aneurysm			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
influenza			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	4 / 2579 (0.16%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	1 / 1	1 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
intervertebral discitis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
klebsiella bacteraemia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
localised infection			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
lower respiratory tract infection			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
lung abscess			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
lymph node tuberculosis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
meningoencephalitis bacterial			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
necrotising fasciitis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ophthalmic herpes zoster			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
oral fungal infection			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
orchitis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed[36]	0 / 66 (0.00%)	1 / 548 (0.18%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

osteomyelitis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
otitis media			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	3 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
paracoccidioides infection			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
paronychia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pelvic abscess			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
perirectal abscess			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
peritonitis			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
plasmodium falciparum infection			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
plasmodium vivax infection			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pneumonia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	15 / 297 (5.05%)	34 / 2579 (1.32%)	10 / 592 (1.69%)
occurrences causally related to treatment / all	11 / 17	20 / 36	11 / 14
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 1
pneumonia bacterial			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pneumonia cryptococcal			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pneumonia influenzal			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	2 / 297 (0.67%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	3 / 3	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

pneumonia legionella			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pneumonia viral			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
post procedural infection			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
postoperative abscess			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
postoperative wound infection			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pseudomonal bacteraemia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
psoas abscess			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pulmonary tuberculosis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pyelitis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pyelonephritis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	3 / 2579 (0.12%)	4 / 592 (0.68%)
occurrences causally related to treatment / all	0 / 0	1 / 3	3 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pyelonephritis acute			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	2 / 297 (0.67%)	2 / 2579 (0.08%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 5	2 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
respiratory syncytial virus infection			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
respiratory tract infection			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	2 / 297 (0.67%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

salpingitis alternative dictionary used: MedDRA 23.1			
subjects affected / exposed[37]	0 / 231 (0.00%)	1 / 2031 (0.05%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
sepsis alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	3 / 297 (1.01%)	10 / 2579 (0.39%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	2 / 4	5 / 10	1 / 1
deaths causally related to treatment / all	0 / 0	2 / 3	0 / 0
septic shock alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	4 / 2579 (0.16%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	2 / 4	1 / 1
deaths causally related to treatment / all	0 / 0	2 / 3	0 / 0
sinusitis alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
sinusitis bacterial alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
skin infection alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
staphylococcal bacteraemia alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
staphylococcal sepsis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
subcutaneous abscess			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
systemic infection			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
testicular abscess			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed[38]	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 152 (0.66%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
thrombophlebitis septic			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
tooth abscess			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

tuberculosis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
upper respiratory tract infection			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	4 / 2579 (0.16%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	2 / 4	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
urinary tract infection			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	4 / 297 (1.35%)	12 / 2579 (0.47%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	3 / 7	7 / 12	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
urinary tract infection bacterial			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	2 / 297 (0.67%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
urinary tract infection enterococcal			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
urosepsis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	4 / 2579 (0.16%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 6	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
varicella			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
varicella zoster virus infection			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
viral infection			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	2 / 2579 (0.08%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
vulvitis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed[39]	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 440 (0.23%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
wound abscess			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 297 (0.34%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
wound infection			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
wound sepsis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Metabolism and nutrition disorders			
dehydration			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	4 / 2579 (0.16%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
diabetes mellitus			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
diabetic ketoacidosis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	2 / 2579 (0.08%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
diabetic metabolic decompensation			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
electrolyte imbalance			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
hyperglycaemia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
hyperkalaemia			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 297 (0.00%)	0 / 2579 (0.00%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
hypokalaemia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	3 / 2579 (0.12%)	1 / 592 (0.17%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
hyponatraemia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
obesity			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	2 / 297 (0.67%)	0 / 2579 (0.00%)	2 / 592 (0.34%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
type 2 diabetes mellitus			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 297 (0.00%)	1 / 2579 (0.04%)	0 / 592 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	4 mg Baricitinib Step-Down		
Total subjects affected by serious adverse events			
subjects affected / exposed	178 / 594 (29.97%)		
number of deaths (all causes)	14		
number of deaths resulting from adverse events	5		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
adenocarcinoma of colon			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	1 / 1			
adenocarcinoma pancreas				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
anaplastic meningioma				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
angiolipoma				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
basal cell carcinoma				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
benign neoplasm of skin				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
benign neoplasm of thyroid gland				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			

bladder cancer				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
bowen's disease				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
brain neoplasm				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
breast cancer				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	2 / 594 (0.34%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
breast cancer metastatic				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	2 / 594 (0.34%)			
occurrences causally related to treatment / all	1 / 2			
deaths causally related to treatment / all	0 / 0			
cervix carcinoma				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed[1]	0 / 448 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
cervix carcinoma stage 0				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed[2]	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
clear cell renal cell carcinoma			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
colon adenoma			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
colon cancer			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 594 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
colorectal cancer stage iv			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 594 (0.17%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
diffuse large b-cell lymphoma			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 594 (0.17%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
extranodal marginal zone b-cell lymphoma (malt type)			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
fibrous histiocytoma				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
gallbladder cancer				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	1 / 1			
gastric cancer				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	2 / 594 (0.34%)			
occurrences causally related to treatment / all	2 / 2			
deaths causally related to treatment / all	0 / 0			
gastric neoplasm				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
giant cell tumour of tendon sheath				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
intraductal proliferative breast lesion				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

invasive ductal breast carcinoma				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
large granular lymphocytosis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
large intestine fibroma				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
laryngeal cancer				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
lentigo maligna				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
leukaemia				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
lipoma				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
lung adenocarcinoma			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
lung adenocarcinoma stage iv			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
lung cancer metastatic			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
lung neoplasm			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
lung neoplasm malignant			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
lung squamous cell carcinoma metastatic			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
lymphocytic leukaemia				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
lymphoproliferative disorder				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
malignant fibrous histiocytoma				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
malignant glioma				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
malignant melanoma				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	2 / 594 (0.34%)			
occurrences causally related to treatment / all	3 / 4			
deaths causally related to treatment / all	0 / 0			
malignant melanoma in situ				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

malignant peritoneal neoplasm				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
malignant pleural effusion				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
meningioma				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
metastases to central nervous system				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
metastases to peritoneum				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
metastatic gastric cancer				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
mucoepidermoid carcinoma				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
mueller's mixed tumour			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed[3]	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
neoplasm malignant			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 594 (0.17%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
neuroendocrine carcinoma of the skin			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
non-hodgkin's lymphoma			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 594 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
non-small cell lung cancer metastatic			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
nonkeratinising carcinoma of nasopharynx			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
oesophageal squamous cell carcinoma			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
oral neoplasm benign			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
ovarian adenoma			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed[4]	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
ovarian cancer			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed[5]	1 / 448 (0.22%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
ovarian cancer stage iv			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed[6]	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
ovarian germ cell teratoma benign			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed[7]	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
paget's disease of nipple			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 594 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
pancreatic carcinoma			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
pancreatic carcinoma metastatic			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
pancreatic carcinoma stage iv			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
papillary cystadenoma lymphomatosum			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
papillary thyroid cancer			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
prostate cancer			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed[8]	0 / 146 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
prostate cancer metastatic			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed[9]	1 / 146 (0.68%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
prostatic adenoma			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed[10]	1 / 146 (0.68%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
rectal cancer			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 594 (0.17%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
renal cancer			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
renal cell carcinoma			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

skin cancer				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
small cell lung cancer metastatic				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
squamous cell carcinoma				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
squamous cell carcinoma of lung				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
squamous cell carcinoma of skin				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
squamous cell carcinoma of the cervix				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed[11]	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
squamous cell carcinoma of the parotid gland				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
t-cell lymphoma				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
thyroid cancer stage i				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
uterine cancer				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed[12]	0 / 448 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
uterine carcinoma in situ				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed[13]	0 / 448 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
uterine leiomyoma				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed[14]	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Vascular disorders				
aortic arteriosclerosis				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
deep vein thrombosis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	4 / 594 (0.67%)			
occurrences causally related to treatment / all	4 / 4			
deaths causally related to treatment / all	0 / 0			
embolism arterial				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
essential hypertension				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
haematoma				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
haemorrhage				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
hypertension				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

hypertensive crisis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
hypotension				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
hypovolaemic shock				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
intermittent claudication				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
jugular vein thrombosis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
necrosis ischaemic				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
peripheral artery stenosis				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
peripheral ischaemia				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
peripheral venous disease				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
rheumatoid vasculitis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
thrombophlebitis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
thrombosed varicose vein				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
varicose vein				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			

vasculitis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
venous thrombosis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
venous thrombosis limb				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Surgical and medical procedures				
arthrodesis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
cataract operation				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
finger amputation				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
hysterectomy				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed[15]	0 / 448 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
internal fixation of fracture			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
joint arthroplasty			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
knee arthroplasty			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 594 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
limb reconstructive surgery			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
rehabilitation therapy			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
scar excision			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

shoulder arthroplasty				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
vaginal cyst excision				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed[16]	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pregnancy, puerperium and perinatal conditions				
abortion spontaneous				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed[17]	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
pregnancy				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed[18]	0 / 448 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
General disorders and administration site conditions				
adverse drug reaction				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
alcohol interaction				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
chest pain				

alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
complication associated with device				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
death				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
exercise tolerance decreased				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
general physical health deterioration				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
mucosal inflammation				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	2 / 2			
deaths causally related to treatment / all	0 / 0			
multiple organ dysfunction syndrome				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
non-cardiac chest pain				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
pain				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
pyrexia				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
sudden cardiac death				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
systemic inflammatory response syndrome				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Immune system disorders				
anaphylactic reaction				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
hypersensitivity				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Social circumstances				
respite care				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Reproductive system and breast disorders				
adnexa uteri cyst				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed[19]	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
bartholin's cyst				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed[20]	1 / 448 (0.22%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
benign prostatic hyperplasia				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed[21]	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
cervical cyst				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed[22]	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
cervical dysplasia				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed[23]	1 / 448 (0.22%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
dysfunctional uterine bleeding				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed[24]	1 / 448 (0.22%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
endometrial hyperplasia				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed[25]	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
endometrial hypertrophy				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed[26]	1 / 448 (0.22%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
endometriosis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed[27]	0 / 448 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
genital prolapse				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

metrorrhagia				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed[28]	1 / 448 (0.22%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 0			
ovarian cyst				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed[29]	1 / 448 (0.22%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
pelvic pain				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
testicular cyst				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed[30]	1 / 146 (0.68%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
uterine polyp				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed[31]	1 / 448 (0.22%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
uterine prolapse				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed[32]	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
vaginal haemorrhage				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed[33]	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
vaginal prolapse				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed[34]	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Respiratory, thoracic and mediastinal disorders				
acute pulmonary oedema				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
acute respiratory distress syndrome				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
acute respiratory failure				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	2 / 594 (0.34%)			
occurrences causally related to treatment / all	1 / 2			
deaths causally related to treatment / all	1 / 2			
allergic bronchitis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
asthma				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
atelectasis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
bronchitis chronic			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 594 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
bronchopneumopathy			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 594 (0.17%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
bronchospasm			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
chronic obstructive pulmonary disease			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 594 (0.17%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
cough			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
interstitial lung disease				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	2 / 594 (0.34%)			
occurrences causally related to treatment / all	2 / 3			
deaths causally related to treatment / all	1 / 1			
lung disorder				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
nasal polyps				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
obstructive airways disorder				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
organising pneumonia				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
pleural effusion				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

pleurisy				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
pneumonia aspiration				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
pneumonitis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
pneumothorax				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
pulmonary arterial hypertension				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
pulmonary embolism				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	3 / 594 (0.51%)			
occurrences causally related to treatment / all	3 / 3			
deaths causally related to treatment / all	0 / 0			
pulmonary hypertension				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
pulmonary mass				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
pulmonary oedema				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	2 / 594 (0.34%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
respiratory arrest				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
respiratory failure				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	2 / 594 (0.34%)			
occurrences causally related to treatment / all	1 / 2			
deaths causally related to treatment / all	0 / 0			
sleep apnoea syndrome				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
vocal cord polyp				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

Psychiatric disorders			
anxiety			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
confusional state			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
depressed mood			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
depression			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 594 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
mental disorder			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
mental status changes			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
suicidal ideation			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
suicide attempt				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Product issues				
device dislocation				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
device failure				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
device loosening				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Hepatobiliary disorders				
bile duct stone				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	2 / 594 (0.34%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
biliary colic				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
biliary obstruction				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
cholangitis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
cholecystitis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	3 / 594 (0.51%)			
occurrences causally related to treatment / all	1 / 5			
deaths causally related to treatment / all	0 / 0			
cholecystitis acute				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	2 / 594 (0.34%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
cholecystitis chronic				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
cholelithiasis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	10 / 594 (1.68%)			
occurrences causally related to treatment / all	2 / 10			
deaths causally related to treatment / all	0 / 0			

gallbladder polyp				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
hepatic cirrhosis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
liver disorder				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
nonalcoholic fatty liver disease				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Investigations				
blood creatine phosphokinase increased				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
blood glucose increased				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
blood pressure increased				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
cardiac murmur				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
electrocardiogram t wave inversion				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
electrocardiogram change				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
glomerular filtration rate decreased				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
haemoglobin decreased				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
influenza a virus test positive				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

mycobacterium tuberculosis complex test positive				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
transaminases increased				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Injury, poisoning and procedural complications				
accident				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
ankle fracture				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
brain herniation				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
burns second degree				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
carbon monoxide poisoning				
alternative dictionary used:				

MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
cervical vertebral fracture				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
colon injury				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
compression fracture				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
contusion				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
crush injury				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
dislocation of vertebra				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
epiphyseal injury				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
face injury				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
fall				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	3 / 594 (0.51%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 0			
femoral neck fracture				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
femur fracture				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
fibula fracture				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

foot fracture				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
hand fracture				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
head injury				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
hip fracture				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
humerus fracture				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	3 / 594 (0.51%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 0			
injury				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
joint dislocation				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
joint injury				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
keratorhexis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
ligament rupture				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
lower limb fracture				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 0			
lumbar vertebral fracture				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
meniscus injury				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			

open globe injury				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
open fracture				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
overdose				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
patella fracture				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
pelvic fracture				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
periprosthetic fracture				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
post procedural complication				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
post procedural haematoma				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
post procedural haemorrhage				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
radius fracture				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
rib fracture				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
road traffic accident				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
scapula fracture				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

seroma				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
skin wound				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
skull fracture				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
spinal compression fracture				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
suture rupture				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
synovial rupture				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
tendon injury				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
tendon rupture			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 594 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
thoracic vertebral fracture			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 594 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
tibia fracture			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	4 / 594 (0.67%)		
occurrences causally related to treatment / all	0 / 7		
deaths causally related to treatment / all	0 / 0		
toxicity to various agents			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
traumatic arthritis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 594 (0.17%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
upper limb fracture			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	2 / 594 (0.34%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		

wound				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
wound dehiscence				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
wrist fracture				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Congenital, familial and genetic disorders				
congenital central nervous system anomaly				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
hydrocele				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed[35]	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
hypertrophic cardiomyopathy				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cardiac disorders				

acute coronary syndrome				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
acute left ventricular failure				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
acute myocardial infarction				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
angina pectoris				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
angina unstable				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
aortic valve disease				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
aortic valve incompetence				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
aortic valve stenosis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
arteriosclerosis coronary artery				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
atrial fibrillation				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	3 / 594 (0.51%)			
occurrences causally related to treatment / all	0 / 4			
deaths causally related to treatment / all	0 / 0			
atrial tachycardia				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
atrioventricular block complete				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
bradycardia				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

bundle branch block left				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
cardiac arrest				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
cardiac failure				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	2 / 594 (0.34%)			
occurrences causally related to treatment / all	0 / 5			
deaths causally related to treatment / all	0 / 2			
cardiac failure acute				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
cardiac failure chronic				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
cardiac failure congestive				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
cardio-respiratory arrest				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
chronic left ventricular failure				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
coronary artery disease				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
coronary artery occlusion				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
coronary artery stenosis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
mitral valve disease				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
mitral valve incompetence				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	2 / 594 (0.34%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			

myocardial infarction				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
myocardial ischaemia				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
palpitations				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
pericarditis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
right ventricular failure				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
sinus node dysfunction				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
sinus tachycardia				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
stress cardiomyopathy				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
supraventricular tachycardia				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
ventricular arrhythmia				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
ventricular fibrillation				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
ventricular tachycardia				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Nervous system disorders				
amyotrophic lateral sclerosis				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
autonomic neuropathy				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
basal ganglia haemorrhage				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
central nervous system vasculitis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
cerebellar infarction				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
cerebellar stroke				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
cerebral artery stenosis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

cerebral artery thrombosis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
cerebral haemorrhage			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 594 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
cerebral infarction			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	2 / 594 (0.34%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
cerebral microhaemorrhage			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
cerebral thrombosis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 594 (0.17%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
cerebral venous thrombosis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
cerebrospinal fistula			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
cerebrovascular accident				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
cerebrospinal fluid leakage				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
cerebrovascular disorder				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
cervical cord compression				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
cervical radiculopathy				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
dementia				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

depressed level of consciousness				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
dizziness				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
embolic stroke				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
epilepsy				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
haemorrhage intracranial				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
haemorrhagic stroke				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
headache				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
hemiparesis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
intercostal neuralgia				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
intracranial aneurysm				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
ischaemic cerebral infarction				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
ischaemic stroke				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
leukoencephalopathy				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

loss of consciousness				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
metabolic encephalopathy				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
migraine				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
myelopathy				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
neuralgia				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
neuropathy peripheral				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
peripheral sensorimotor neuropathy				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
post herpetic neuralgia				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
presyncope				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
radiculopathy				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
sciatica				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
seizure				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
sensory disturbance				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

subarachnoid haemorrhage				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
syncope				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
thalamus haemorrhage				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
transient ischaemic attack				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Blood and lymphatic system disorders				
anaemia				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	3 / 594 (0.51%)			
occurrences causally related to treatment / all	2 / 5			
deaths causally related to treatment / all	0 / 0			
coagulopathy				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
febrile neutropenia				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
leukocytosis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
lymphopenia				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
normochromic normocytic anaemia				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
normocytic anaemia				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
pancytopenia				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
thrombocytopenia				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

thrombocytosis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ear and labyrinth disorders				
conductive deafness				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
deafness unilateral				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
meniere's disease				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
sudden hearing loss				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
vertigo				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
vertigo positional				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Eye disorders			
cataract			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 594 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
cataract subcapsular			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 594 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
corneal perforation			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
dry age-related macular degeneration			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
glaucoma			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 594 (0.17%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
keratitis			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
macular rupture				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
ocular hypertension				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
retinal detachment				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
rhegmatogenous retinal detachment				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastrointestinal disorders				
abdominal pain				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
abdominal pain upper				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
abdominal wall haematoma				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
anal fistula				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
colitis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
colitis ischaemic				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
colitis ulcerative				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
dental cyst				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

diarrhoea				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
diverticular perforation				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
diverticulum				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
diverticulum intestinal				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
duodenal ulcer haemorrhage				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
duodenitis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
dysphagia				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
enterocolitis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
gastric ulcer				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
gastric ulcer haemorrhage				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
gastric ulcer perforation				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
gastritis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
gastritis erosive				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

gastrointestinal haemorrhage				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
gastrooesophageal reflux disease				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
haemorrhoids				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
hiatus hernia				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
ileus				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
inguinal hernia				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
intestinal obstruction				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
intestinal perforation				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
irritable bowel syndrome				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
obstructive pancreatitis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
oesophageal stenosis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
pancreatitis acute				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
parotid gland enlargement				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

rectal haemorrhage				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
rectal polyp				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
reflux gastritis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
small intestinal obstruction				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
umbilical hernia				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	2 / 594 (0.34%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
upper gastrointestinal haemorrhage				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
volvulus				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
vomiting				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Skin and subcutaneous tissue disorders				
actinic keratosis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
angioedema				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
diabetic ulcer				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
eczema asteatotic				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
granuloma skin				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
skin necrosis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
skin ulcer				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Renal and urinary disorders				
acute kidney injury				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
bladder prolapse				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
calculus bladder				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
calculus urinary				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
chronic kidney disease				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
glomerulonephritis membranous				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
hydronephrosis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
iga nephropathy				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
nephrolithiasis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
oliguria				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

proteinuria				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
renal colic				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
renal cyst				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
renal injury				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
renal pain				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
renal vein thrombosis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
stress urinary incontinence				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
tubulointerstitial nephritis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
ureterolithiasis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 0			
urinary tract inflammation				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Endocrine disorders				
adrenal suppression				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
goitre				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
hyperparathyroidism				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
acquired claw toe			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
arthralgia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
arthritis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
back pain			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
cervical spinal stenosis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
chondrocalcinosis pyrophosphate			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
diastasis recti abdominis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
foot deformity				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	6 / 594 (1.01%)			
occurrences causally related to treatment / all	0 / 7			
deaths causally related to treatment / all	0 / 0			
fracture delayed union				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
haematoma muscle				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
intervertebral disc compression				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
intervertebral disc degeneration				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

intervertebral disc disorder				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
intervertebral disc protrusion				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	2 / 594 (0.34%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
joint destruction				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
lumbar spinal stenosis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
mixed connective tissue disease				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
muscular weakness				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
musculoskeletal chest pain				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
osteoarthritis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	5 / 594 (0.84%)			
occurrences causally related to treatment / all	0 / 5			
deaths causally related to treatment / all	0 / 0			
osteochondrosis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
osteonecrosis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
osteoporosis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
osteoporotic fracture				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
pain in extremity				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

rhabdomyolysis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
rheumatoid arthritis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	3 / 594 (0.51%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 0			
rheumatoid nodule				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
rotator cuff syndrome				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
scoliosis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
spinal instability				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
spinal osteoarthritis				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
spinal pain				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
spinal stenosis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
spondyloarthropathy				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
spondylolisthesis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 0			
synovial cyst				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
synovitis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

tendonitis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
tenosynovitis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	2 / 2			
deaths causally related to treatment / all	0 / 0			
Infections and infestations				
abdominal infection				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
abdominal wall abscess				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
abscess intestinal				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
abscess limb				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	3 / 594 (0.51%)			
occurrences causally related to treatment / all	2 / 4			
deaths causally related to treatment / all	0 / 0			
anal abscess				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
appendicitis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	4 / 594 (0.67%)			
occurrences causally related to treatment / all	1 / 4			
deaths causally related to treatment / all	0 / 0			
appendicitis perforated				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
arthritis bacterial				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
arthritis infective				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
atypical pneumonia				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
bacteraemia				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

bacterial infection				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
bone tuberculosis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
breast abscess				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
bronchitis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	5 / 594 (0.84%)			
occurrences causally related to treatment / all	6 / 7			
deaths causally related to treatment / all	0 / 0			
bronchitis viral				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
bursitis infective				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
bursitis infective staphylococcal				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
covid-19				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
covid-19 pneumonia				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
cellulitis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	4 / 594 (0.67%)			
occurrences causally related to treatment / all	4 / 5			
deaths causally related to treatment / all	0 / 0			
cholecystitis infective				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
chronic sinusitis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	2 / 594 (0.34%)			
occurrences causally related to treatment / all	1 / 2			
deaths causally related to treatment / all	0 / 0			
chronic tonsillitis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

coronavirus infection				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
cystitis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
cytomegalovirus hepatitis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
cytomegalovirus infection				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
dengue fever				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
device related infection				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
device related sepsis				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
disseminated tuberculosis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
diverticulitis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
empyema				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
encephalitis viral				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
endocarditis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
endocarditis bacterial				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

enteritis infectious				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
enterobacter pneumonia				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
enterocolitis infectious				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
erysipelas				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
escherichia sepsis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
extrapulmonary tuberculosis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
fascial infection				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
gangrene				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
gastroenteritis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	2 / 594 (0.34%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
gastroenteritis norovirus				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
gastroenteritis salmonella				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
gastroenteritis viral				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
groin abscess				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

h1n1 influenza				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
haematoma infection				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
helicobacter gastritis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
hepatitis e				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
herpes zoster				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	5 / 594 (0.84%)			
occurrences causally related to treatment / all	4 / 5			
deaths causally related to treatment / all	0 / 0			
herpes zoster infection neurological				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
herpes zoster meningitis				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
histoplasmosis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
implant site infection				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
incision site cellulitis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
infected dermal cyst				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
infected skin ulcer				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
infection				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

infectious pleural effusion				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
infective aneurysm				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
influenza				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
intervertebral discitis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
klebsiella bacteraemia				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
localised infection				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
lower respiratory tract infection				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
lung abscess				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
lymph node tuberculosis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 0			
meningoencephalitis bacterial				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
necrotising fasciitis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
ophthalmic herpes zoster				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
oral fungal infection				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

orchitis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed[36]	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
osteomyelitis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
otitis media				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
paracoccidioides infection				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
paronychia				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
pelvic abscess				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
perirectal abscess				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
peritonitis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
plasmodium falciparum infection				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
plasmodium vivax infection				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
pneumonia				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	12 / 594 (2.02%)			
occurrences causally related to treatment / all	8 / 15			
deaths causally related to treatment / all	0 / 2			
pneumonia bacterial				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
pneumonia cryptococcal				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

pneumonia influenzal				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	2 / 2			
deaths causally related to treatment / all	0 / 0			
pneumonia legionella				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
pneumonia viral				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
post procedural infection				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
postoperative abscess				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
postoperative wound infection				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
pseudomonal bacteraemia				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
psoas abscess			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
pulmonary tuberculosis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 594 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
pyelitis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 594 (0.17%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
pyelonephritis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
pyelonephritis acute			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 594 (0.17%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
respiratory syncytial virus infection			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

respiratory tract infection				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
salpingitis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed[37]	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
sepsis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	2 / 594 (0.34%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
septic shock				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
sinusitis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
sinusitis bacterial				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
skin infection				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
staphylococcal bacteraemia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 594 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
staphylococcal sepsis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
subcutaneous abscess			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 594 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
systemic infection			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
testicular abscess			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed[38]	0 / 146 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
thrombophlebitis septic			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

tooth abscess				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
tuberculosis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	2 / 594 (0.34%)			
occurrences causally related to treatment / all	2 / 2			
deaths causally related to treatment / all	0 / 0			
upper respiratory tract infection				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
urinary tract infection				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	3 / 594 (0.51%)			
occurrences causally related to treatment / all	2 / 4			
deaths causally related to treatment / all	0 / 0			
urinary tract infection bacterial				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
urinary tract infection enterococcal				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
urosepsis				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	1 / 1			
varicella				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
varicella zoster virus infection				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
viral infection				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
vulvitis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed[39]	0 / 448 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
wound abscess				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
wound infection				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

wound sepsis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	4 / 4			
deaths causally related to treatment / all	0 / 0			
Metabolism and nutrition disorders				
dehydration				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
diabetes mellitus				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
diabetic ketoacidosis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	1 / 594 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
diabetic metabolic decompensation				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
electrolyte imbalance				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
hyperglycaemia				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
hyperkalaemia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 594 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
hypokalaemia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
hyponatraemia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 594 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
obesity			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
type 2 diabetes mellitus			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Notes:

[1] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.
[2] - The number of subjects exposed to this adverse event is less than the total number of subjects

exposed to this adverse event. These numbers are expected to be equal.

Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.

[3] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.

[4] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.

[5] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.

[6] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.

[7] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.

[8] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.

[9] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.

[10] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.

[11] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.

[12] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.

[13] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.

[14] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.

[15] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.

[16] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.

[17] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.

[18] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.

[19] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.
[20] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.
[21] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.
[22] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.
[23] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.
[24] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.
[25] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.
[26] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.
[27] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.
[28] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.
[29] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.
[30] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.
[31] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.
[32] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.
[33] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.
[34] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.
[35] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
Justification: Gender specific events occurring only in male or female participants have had the number

of participants At Risk adjusted accordingly.

[36] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.

[37] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.

[38] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.

[39] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	2 mg Baricitinib	4 mg Baricitinib	2 mg Baricitinib Step-Down
Total subjects affected by non-serious adverse events			
subjects affected / exposed	234 / 297 (78.79%)	1532 / 2579 (59.40%)	270 / 592 (45.61%)
Investigations			
blood creatine phosphokinase increased			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	22 / 297 (7.41%)	176 / 2579 (6.82%)	20 / 592 (3.38%)
occurrences (all)	26	229	26
Vascular disorders			
hypertension			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	33 / 297 (11.11%)	196 / 2579 (7.60%)	38 / 592 (6.42%)
occurrences (all)	36	218	38
Nervous system disorders			
headache			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	19 / 297 (6.40%)	90 / 2579 (3.49%)	0 / 592 (0.00%)
occurrences (all)	21	106	0
Blood and lymphatic system disorders			
anaemia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	18 / 297 (6.06%)	126 / 2579 (4.89%)	0 / 592 (0.00%)
occurrences (all)	21	156	0
General disorders and administration site conditions			

pyrexia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	16 / 297 (5.39%)	56 / 2579 (2.17%)	0 / 592 (0.00%)
occurrences (all)	17	62	0
Gastrointestinal disorders			
constipation			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	20 / 297 (6.73%)	72 / 2579 (2.79%)	0 / 592 (0.00%)
occurrences (all)	24	79	0
diarrhoea			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	18 / 297 (6.06%)	87 / 2579 (3.37%)	0 / 592 (0.00%)
occurrences (all)	25	107	0
Respiratory, thoracic and mediastinal disorders			
cough			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	28 / 297 (9.43%)	105 / 2579 (4.07%)	35 / 592 (5.91%)
occurrences (all)	46	134	37
Psychiatric disorders			
insomnia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	16 / 297 (5.39%)	47 / 2579 (1.82%)	0 / 592 (0.00%)
occurrences (all)	16	50	0
Musculoskeletal and connective tissue disorders			
arthralgia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	43 / 297 (14.48%)	155 / 2579 (6.01%)	0 / 592 (0.00%)
occurrences (all)	58	229	0
back pain			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	42 / 297 (14.14%)	162 / 2579 (6.28%)	35 / 592 (5.91%)
occurrences (all)	55	181	41
pain in extremity			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	16 / 297 (5.39%)	53 / 2579 (2.06%)	0 / 592 (0.00%)
occurrences (all)	25	63	0
rheumatoid arthritis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	27 / 297 (9.09%)	141 / 2579 (5.47%)	0 / 592 (0.00%)
occurrences (all)	38	250	0
Infections and infestations			
bronchitis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	48 / 297 (16.16%)	291 / 2579 (11.28%)	44 / 592 (7.43%)
occurrences (all)	65	431	61
herpes zoster			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	30 / 297 (10.10%)	160 / 2579 (6.20%)	39 / 592 (6.59%)
occurrences (all)	32	167	42
influenza			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	15 / 297 (5.05%)	147 / 2579 (5.70%)	30 / 592 (5.07%)
occurrences (all)	16	176	35
nasopharyngitis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	42 / 297 (14.14%)	291 / 2579 (11.28%)	54 / 592 (9.12%)
occurrences (all)	95	488	109
pharyngitis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	19 / 297 (6.40%)	119 / 2579 (4.61%)	0 / 592 (0.00%)
occurrences (all)	30	181	0
pneumonia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	17 / 297 (5.72%)	66 / 2579 (2.56%)	0 / 592 (0.00%)
occurrences (all)	19	71	0
sinusitis			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	23 / 297 (7.74%)	100 / 2579 (3.88%)	0 / 592 (0.00%)
occurrences (all)	31	121	0
upper respiratory tract infection			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	58 / 297 (19.53%)	281 / 2579 (10.90%)	46 / 592 (7.77%)
occurrences (all)	106	454	54
urinary tract infection			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	53 / 297 (17.85%)	241 / 2579 (9.34%)	34 / 592 (5.74%)
occurrences (all)	84	336	48
Metabolism and nutrition disorders			
hypercholesterolaemia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	16 / 297 (5.39%)	142 / 2579 (5.51%)	18 / 592 (3.04%)
occurrences (all)	19	162	18
hyperlipidaemia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	18 / 297 (6.06%)	133 / 2579 (5.16%)	0 / 592 (0.00%)
occurrences (all)	20	157	0

Non-serious adverse events	4 mg Baricitinib Step-Down		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	315 / 594 (53.03%)		
Investigations			
blood creatine phosphokinase increased			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	33 / 594 (5.56%)		
occurrences (all)	44		
Vascular disorders			
hypertension			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	46 / 594 (7.74%)		
occurrences (all)	47		
Nervous system disorders			

headache alternative dictionary used: MedDRA 23.1 subjects affected / exposed occurrences (all)	 0 / 594 (0.00%) 0		
Blood and lymphatic system disorders anaemia alternative dictionary used: MedDRA 23.1 subjects affected / exposed occurrences (all)	 0 / 594 (0.00%) 0		
General disorders and administration site conditions pyrexia alternative dictionary used: MedDRA 23.1 subjects affected / exposed occurrences (all)	 0 / 594 (0.00%) 0		
Gastrointestinal disorders constipation alternative dictionary used: MedDRA 23.1 subjects affected / exposed occurrences (all) diarrhoea alternative dictionary used: MedDRA 23.1 subjects affected / exposed occurrences (all)	 0 / 594 (0.00%) 0 0 / 594 (0.00%) 0		
Respiratory, thoracic and mediastinal disorders cough alternative dictionary used: MedDRA 23.1 subjects affected / exposed occurrences (all)	 25 / 594 (4.21%) 32		
Psychiatric disorders insomnia alternative dictionary used: MedDRA 23.1 subjects affected / exposed occurrences (all)	 0 / 594 (0.00%) 0		
Musculoskeletal and connective tissue disorders			

arthralgia				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences (all)	0			
back pain				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	36 / 594 (6.06%)			
occurrences (all)	43			
pain in extremity				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences (all)	0			
rheumatoid arthritis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	0 / 594 (0.00%)			
occurrences (all)	0			
Infections and infestations				
bronchitis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	65 / 594 (10.94%)			
occurrences (all)	91			
herpes zoster				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	53 / 594 (8.92%)			
occurrences (all)	57			
influenza				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	56 / 594 (9.43%)			
occurrences (all)	64			
nasopharyngitis				
alternative dictionary used: MedDRA 23.1				
subjects affected / exposed	58 / 594 (9.76%)			
occurrences (all)	101			
pharyngitis				
alternative dictionary used: MedDRA 23.1				

subjects affected / exposed	0 / 594 (0.00%)		
occurrences (all)	0		
pneumonia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences (all)	0		
sinusitis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences (all)	0		
upper respiratory tract infection			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	51 / 594 (8.59%)		
occurrences (all)	63		
urinary tract infection			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	52 / 594 (8.75%)		
occurrences (all)	72		
Metabolism and nutrition disorders			
hypercholesterolaemia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	32 / 594 (5.39%)		
occurrences (all)	32		
hyperlipidaemia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 594 (0.00%)		
occurrences (all)	0		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
21 March 2014	Amendment (d): Allowed additional enrollment of participants and extend duration of study.
30 October 2014	Amendment (e): Allowed for additional 24 months of treatment duration.
30 January 2017	Amendment (f): Allowed for additional 12 months of treatment duration.
11 December 2017	Amendment (g): Allowed for an additional 24 months of treatment duration.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported